細胞培養市場規模、シェア、動向、2031年までの世界予測

細胞培養市場は、2026年の推定330億7,000万米ドルから、2031年には584億2,000万米ドルに成長し、2026年から2031年の予測期間における年平均成長率（CAGR）は12.1%に達するとMarketsandMarketsでは予測しています。この市場の成長は、細胞生物学研究への投資や資金提供の増加によるものです。がんなどの慢性疾患の発生率が増加していることで、組織工学や再生医療といった高度な治療法への需要が高まっており、こうした傾向が今後数年間の細胞培養市場の成長を牽引すると予想されます。

調査対象範囲

本調査レポートでは、細胞培養市場を以下の区分で分析しています：製品別［消耗品（血清、培地、試薬、容器、その他消耗品・アクセサリー）、機器（周辺機器、バイオリアクター、保管機器）］、用途別［バイオ医薬品製造（モノクローナル抗体製造、ワクチン製造、その他治療用タンパク質製造）、診断、組織工学・再生医療（細胞・遺伝子治療、その他組織工学・再生医療用途）、創薬スクリーニング・開発、その他用途］、エンドユーザー別［製薬・バイオテクノロジー企業、病院・検査機関、学術・研究機関、その他エンドユーザー］、および地域別［北米、欧州、アジア太平洋、中南米、中東・アフリカ］。

本レポートでは、細胞培養市場の成長に影響を与える主要な要因（促進要因、課題、機会、阻害要因など）について詳細な情報を提供しています。また、主要な業界プレーヤーに関する包括的な分析を行い、各社の事業概要、製品ポートフォリオ、および主要戦略（提携、パートナーシップ、事業拡大、契約、買収、市場における最近の動向など）についての知見を提供します。

本レポートを購入するメリット

本レポートは、細胞培養市場の全体像を包括的に提示するものです。様々なセグメントにおける市場規模および将来の成長機会を評価することを目的としています。さらに、主要な市場プレーヤーに関する詳細な競合分析も行っており、各社の企業概要、最近の動向、主要な市場戦略などが網羅されています。

本レポートでは、以下の点に関する知見を提供します。

市場の成長に影響を与える要因の分析：主要な促進要因（細胞ベースの研究への支援・資金提供の拡大、無血清・動物由来成分不使用培地への需要増、モノクローナル抗体やバイオシミラーの普及、シングルユース技術の採用拡大、先端治療医薬品の成長）、阻害要因（細胞生物学研究の高コスト、高密度細胞培養における生産上の制約）、機会（新興国における機会拡大、3D細胞培養への需要増、次世代治療法への注目の高まり）、および課題（細胞利用に関する倫理的懸念、プラスチック製消耗品の廃棄）。

• 製品開発・イノベーション：細胞培養市場における新製品に関する詳細な知見
• 市場展開：有望な市場に関する包括的な情報（地域別の市場分析を含む）
• 市場の多角化：新製品、未開拓地域、最近の動向、投資状況など、細胞培養市場に関する網羅的な情報
• 競合分析：Thermo Fisher Scientific Inc.（米国）、Danaher Corporation（米国）、Sartorius AG（ドイツ）、Merck KGaA（ドイツ）、Corning Incorporated（米国）、富士フイルムホールディングス株式会社（日本）、BD（米国）、Eppendorf SE（ドイツ）、Lonza（スイス）、Getinge AB（スウェーデン）、Agilent Technologies, Inc.（米国）、HiMedia Laboratories（インド）、Miltenyi Biotec（ドイツ）、STEMCELL Technologies（カナダ）、Solida Biotech GmbH（ドイツ）、Caisson Labs（米国）、PromoCell GmbH（ドイツ）、InvivoGen（フランス）、PAN-Biotech（ドイツ）、Cellexus（スコットランド）、Meissner Filtration Products Inc.（米国）、Adolf Kühner AG（スイス）、Bio-Techne（米国）、Advancion Corporation（米国）、BioSpherix, Ltd.（米国）といった主要企業の市場シェア、成長戦略、および製品ラインナップに関する詳細な分析。

本レポートは、ステークホルダーが細胞培養市場の動向を把握するのに役立つほか、市場の主要な促進要因、阻害要因、課題、および機会に関する情報を提供します。また、主要な業界プレーヤーに関する詳細な分析を行い、各社の戦略、製品投入、買収、提携・協力関係、最近の動向、投資・資金調達状況、ブランドや製品の比較、ベンダー評価、さらには細胞培養分野における財務指標などについて、有益な知見を提供します。

Report Description

The cell culture market is projected to reach USD 58.42 billion by 2031 from an estimated USD 33.07 billion in 2026, at a CAGR of 12.1% during the forecast period of 2026 to 2031. The growth of this market can be attributed to increasing investment and funding for research in cell biology. The rising incidence of chronic diseases such as cancer is boosting the demand for advanced therapies such as tissue engineering and regenerative medicine. This trend is expected to drive the growth of the cell culture market in the coming years.

By application, the biopharmaceutical production segment accounted for the largest share of the market in 2025.

In 2025, the biopharmaceutical production segment accounted for the largest share of the application segment in the global cell culture market. The biopharmaceutical production segment is further categorized into vaccine production, monoclonal antibody production, and other therapeutic protein production. The growing prevalence of infectious diseases is boosting demand for biopharmaceuticals such as vaccines, monoclonal antibodies, and therapeutic proteins, thereby promoting the growth of biopharmaceutical production in the cell culture market.

The sera, media, and reagents segment accounted for a major share of the consumables market in 2025.

The cell culture consumables market is categorized by type into sera, media, and reagents; vessels; and accessories. The sera, media, and reagents segment accounted for the largest share of the cell culture consumables market in 2025. The large share of this segment is attributed to repeated bulk purchases and the need for consumables in the biotechnology and pharmaceutical industries. Research labs and production facilities often require large quantities of sera, media, reagents, vessels, and accessories to sustain continuous cell culture activities. This leads to frequent and substantial procurement for experimentation, testing, and manufacturing processes.

The Asia Pacific region is expected to experience the highest CAGR in the cell culture market from 2026 to 2031.

The cell culture market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is expected to register the fastest growth during the forecast period, driven by expanding biologics and biosimilar manufacturing, rising vaccine production, increasing cell & gene therapy activity, and growing government support for domestic biomanufacturing. Countries such as China, India, Japan, South Korea, and Australia are strengthening their cell culture capabilities through investments in biopharmaceutical production, regenerative medicine, stem cell research, and advanced bioprocessing infrastructure. The region is also benefiting from growing CDMO activity, cost-efficient manufacturing, rising clinical research, and wider adoption of serum-free media, single-use systems, culture vessels, reagents, and other cell culture consumables.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), Corning Incorporated (US), FUJIFILM Holdings Corporation (Japan), BD (US), Eppendorf SE (Germany), Lonza (Switzerland), Getinge AB (Sweden), Agilent Technologies, Inc. (US), HiMedia Laboratories (India), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Solida Biotech GmbH (Germany), Plant Cell Technology Inc. (US), PromoCell GmbH (Germany), InvivoGen (France), PAN-Biotech (Germany), Cellexus (Scotland), Meissner Filtration Products Inc. (US), Adolf Kühner AG (Switzerland), Bio-Techne (US), Advancion Corporation (US), and BioSpherix, Ltd. (US) are some of the key companies offering cell culture solutions.

Research Coverage

This research report categorizes the cell culture market by product [consumables (sera, media, reagents; vessels, and other consumables & accessories), equipment (supporting equipment, bioreactors, and storage equipment)], application [biopharmaceutical production (monoclonal antibody production, vaccine production, and other therapeutic protein production), diagnostics, tissue engineering & regenerative medicine (cell & gene therapy and other tissue engineering & regenerative medicine applications), drug screening & development, and other applications], end user (pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the cell culture market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments in the cell culture market.

Key Benefits of Buying the Report

This report offers a comprehensive overview of the cell culture market. It aims to assess the market size and future growth opportunities across various segments. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies

The report provides insights on the following pointers:

Analysis of key drivers (increasing support and funding for cell-based research, rising demand for serum-free and animal component-free media, growing popularity of monoclonal antibodies and biosimilars, increasing adoption of single-use technologies, and growth in advanced therapy medicinal products), restraints (high cost of cell biology research and limitations in producing high-density cell cultures), opportunities (growing opportunities in emerging economies, rising demand for 3D cell culture, and Increasing focus on next-generation therapeutics), and challenges (ethical concern regarding cell usage, and disposal of plastic consumables) influencing the growth of the market.

• Product Development/Innovation: Detailed insights on newly launched products of the cell culture market
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell culture market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), Corning Incorporated (US), FUJIFILM Holdings Corporation (Japan), BD (US), Eppendorf SE (Germany), Lonza (Switzerland), Getinge AB (Sweden), Agilent Technologies, Inc. (US), HiMedia Laboratories (India), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Solida Biotech GmbH (Germany), Caisson Labs (US), PromoCell GmbH (Germany), InvivoGen (France), PAN-Biotech (Germany), Cellexus (Scotland), Meissner Filtration Products Inc. (US), Adolf Kühner AG (Switzerland), Bio-Techne (US), Advancion Corporation (US), and BioSpherix, Ltd. (US).

The report also helps stakeholders understand trends in the cell culture market and provides information on key drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been conducted to offer insights into their strategies, product launches, acquisitions, partnerships, collaborations, recent activities, investments, funding, brand and product comparisons, vendor evaluations, and financial metrics of the cell culture sector.

Table of Contents

1 INTRODUCTION 60
1.1 STUDY OBJECTIVES 60
1.2 MARKET DEFINITION 60
1.2.1 INCLUSIONS & EXCLUSIONS 61
1.3 STUDY SCOPE 61
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 62
1.3.2 YEARS CONSIDERED 63
1.3.3 CURRENCY CONSIDERED 64
1.3.4 UNIT CONSIDERED 64
1.4 STAKEHOLDERS 64
1.5 SUMMARY OF CHANGES 64
2 EXECUTIVE SUMMARY 66
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 66
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 68
2.3 DISRUPTIVE TRENDS IN CELL CULTURE MARKET 69
2.4 HIGH-GROWTH SEGMENTS 70
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 71
3 PREMIUM INSIGHTS 72
3.1 CELL CULTURE MARKET OVERVIEW 72
3.2 NORTH AMERICA: CELL CULTURE MARKET, BY CONSUMABLE AND COUNTRY 73
3.3 CELL CULTURE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 74
3.4 CELL CULTURE MARKET SHARE, BY END USER 74
4 MARKET OVERVIEW 75
4.1 INTRODUCTION 75
4.2 MARKET DYNAMICS 75
4.2.1 DRIVERS 76
4.2.1.1 Increasing support and funding for cell-based research 76
4.2.1.2 Rising demand for serum-free and animal component-free media 78
4.2.1.3 Growing popularity of monoclonal antibodies and biosimilars 79
4.2.1.4 Increasing adoption of single-use technologies 82
4.2.1.5 Growth in advanced therapy medicinal products 82
4.2.2 RESTRAINTS 84
4.2.2.1 High cost of cell biology research 84
4.2.2.2 Limitations in producing high-density cell cultures 84
4.2.3 OPPORTUNITIES 85
4.2.3.1 Rising demand for 3D cell culture 85
4.2.3.2 Growth opportunities in emerging economies 86
4.2.3.3 Increasing focus on next-generation therapeutics 87
4.2.4 CHALLENGES 88
4.2.4.1 Disposal of plastic consumables 88
4.2.4.2 Ethical concerns related to cell usage 89
4.3 UNMET NEEDS & WHITE SPACES 90
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 90
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 91
5 INDUSTRY TRENDS 92
5.1 PORTER’S FIVE FORCES ANALYSIS 92
5.1.1 BARGAINING POWER OF SUPPLIERS 93
5.1.2 BARGAINING POWER OF BUYERS 93
5.1.3 THREAT OF NEW ENTRANTS 93
5.1.4 THREAT OF SUBSTITUTES 93
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 93
5.2 MACROECONOMIC OUTLOOK 93
5.2.1 INTRODUCTION 93
5.2.2 GDP TRENDS & FORECAST 94
5.2.3 TRENDS IN GLOBAL CELL CULTURE INDUSTRY 94
5.3 VALUE CHAIN ANALYSIS 95
5.4 ECOSYSTEM ANALYSIS 96
5.5 PRICING ANALYSIS 99
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 99
5.5.2 AVERAGE SELLING PRICE TREND OF CELL CULTURE PRODUCTS, BY REGION 101
5.6 TRADE ANALYSIS 102
5.6.1 IMPORT SCENARIO (HS CODE 382100) 103
5.6.2 EXPORT SCENARIO (HS CODE 382100) 104
5.7 KEY CONFERENCES AND EVENTS, 2026–2027 105
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 106
5.9 INVESTMENT AND FUNDING SCENARIO 107
5.9.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 108
5.10 IMPACT OF 2025 US TARIFFS ON CELL CULTURE MARKET 109
5.10.1 INTRODUCTION 109
5.10.2 KEY TARIFF RATES 109
5.10.3 PRICE IMPACT ANALYSIS 110
5.10.4 IMPACT ON COUNTRY/REGION 111
5.10.4.1 US 111
5.10.4.2 Europe 111
5.10.4.3 Asia Pacific 112
5.10.5 IMPACT ON END-USE INDUSTRIES 112
5.10.5.1 Pharmaceutical & biotech companies 112
5.10.5.2 Hospitals & diagnostic laboratories 113
5.10.5.3 Academic & research institutes 113
5.10.5.4 Contract research organizations & contract development and manufacturing organizations 113
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS 114
6.1 TECHNOLOGY ANALYSIS 114
6.1.1 KEY EMERGING TECHNOLOGIES 114
6.1.1.1 Single-use technology 114
6.1.1.2 Flow cytometry 116
6.1.1.3 Microscopy 116
6.1.2 COMPLEMENTARY TECHNOLOGIES 116
6.1.2.1 High-throughput screening 116
6.1.2.2 Mass spectrometry 116
6.1.3 ADJACENT TECHNOLOGIES 117
6.1.3.1 Microfluidics and organ-on-a-chip 117
6.1.3.2 3D bioprinting 117
6.2 TECHNOLOGY/PRODUCT ROADMAP 118
6.3 PATENT ANALYSIS 118
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR CELL CULTURE PATENTS 119
6.4 FUTURE APPLICATIONS 121
6.5 IMPACT OF AI/GEN AI ON CELL CULTURE MARKET 122
6.5.1 BEST PRACTICES IN CELL CULTURE WORKFLOW 123
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN CELL CULTURE MARKET 124
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 124
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN CELL CULTURE MARKET 124
7 SUSTAINABILITY & REGULATORY LANDSCAPE 126
7.1 REGIONAL REGULATIONS & COMPLIANCE 126
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 126
7.1.2 REGULATORY FRAMEWORK 129
7.1.2.1 North America 129
7.1.2.2 Europe 129
7.1.2.3 Asia Pacific 130
7.1.2.4 Latin America 131
7.1.2.5 Middle East & Africa 131
7.1.3 INDUSTRY STANDARDS 131
7.2 SUSTAINABILITY INITIATIVES 132
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 132
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 133
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 134
8.1 DECISION-MAKING PROCESS 134
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 134
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 134
8.2.2 KEY BUYING CRITERIA, BY END USER 135
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 137
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 137
8.5 MARKET PROFITABILITY 137
9 CELL CULTURE MARKET, BY PRODUCT 138
9.1 INTRODUCTION 139
9.2 CONSUMABLES 139
9.2.1 SERA, MEDIA, AND REAGENTS 143
9.2.1.1 Media 147
9.2.1.1.1 Serum-free media 151
9.2.1.1.1.1 CHO media 156
9.2.1.1.1.1.1 High-yield biologics manufacturing to sustain demand for optimized CHO serum-free media 156
9.2.1.1.1.2 HEK 293 media 159
9.2.1.1.1.2.1 Viral vector manufacturing and transient expression workflows to accelerate HEK 293 media adoption 159
9.2.1.1.1.3 Serum-free stem cell media 163
9.2.1.1.1.3.1 Regenerative medicine, iPSC models, and cell therapy translation to drive specialized stem cell media demand 163
9.2.1.1.1.4 Vero Cell media 166
9.2.1.1.1.4.1 Increasing vaccine manufacturing to support demand for serum-free Vero cell media 166
9.2.1.1.1.5 BHK media 170
9.2.1.1.1.5.1 Vaccine production and viral vector workflows to support demand for BHK serum-free media 170
9.2.1.1.1.6 Other serum-free media 173
9.2.1.1.2 Classical media & salts 176
9.2.1.1.2.1 Standardized basal media and salt solutions to support routine culture, assay reproducibility, and vaccine production 176
9.2.1.1.3 Stem cell culture media 180
9.2.1.1.3.1 Rising use of stem cell models and regenerative medicine workflows to drive demand for specialized culture media 180
9.2.1.1.4 Chemically-defined media 183
9.2.1.1.4.1 Increasing need for reproducible, animal component-free workflows to support biologics and advanced therapy development 183
9.2.1.1.5 Specialty media 187
9.2.1.1.5.1 Suitability for use in selective cell types in bioprocessing and biomanufacturing industries to boost market 187
9.2.1.1.6 Other media 191
9.2.1.2 Reagents 195
9.2.1.2.1 Growth factors 199
9.2.1.2.1.1 Need to regulate cell proliferation, differentiation, and migration to sustain growth 199
9.2.1.2.2 Supplements 202
9.2.1.2.2.1 Need to improve cell growth, nutrient availability, and bioproduction performance to support segment growth 202
9.2.1.2.3 Buffers & chemicals 206
9.2.1.2.3.1 Ability to maintain stable pH levels to facilitate growth 206
9.2.1.2.4 Cell dissociation reagents 209
9.2.1.2.4.1 Ability to minimize cell stress and reduce cell damage to foster growth 209
9.2.1.2.5 Balanced salt solutions 213
9.2.1.2.5.1 Ability to maintain optimal physiological conditions for cell growth and experimentation to assist growth 213
9.2.1.2.6 Attachment & matrix factors 216
9.2.1.2.6.1 Rising adoption of 3D cell culture models to support growth 216
9.2.1.2.7 Antibiotics/Antimycotics 220
9.2.1.2.7.1 Ability to mitigate growth of contaminating bacteria, fungi, and mycoplasma to drive market 220
9.2.1.2.8 Cryoprotective reagents 223
9.2.1.2.8.1 Ability to preserve cell viability during freezing and thawing to aid growth 223
9.2.1.2.9 Contamination detection kits 226
9.2.1.2.9.1 Need for rapid identification of microbial contaminants to promote growth 226
9.2.1.2.10 Other reagents 230
9.2.1.3 Sera 233
9.2.1.3.1 Fetal bovine sera 236
9.2.1.3.1.1 Increasing role of fetal bovine sera in cell proliferation to favor growth 236
9.2.1.3.2 Adult bovine sera 240
9.2.1.3.2.1 Cost-effectiveness to contribute to growth 240
9.2.1.3.3 Other animal sera 243
9.2.2 VESSELS 247
9.2.2.1 Cell factory systems/cell stacks 250
9.2.2.1.1 Efficient and scalable solutions for large-scale expansion to drive adoption 250
9.2.2.2 Roller/roux bottles 254
9.2.2.2.1 Scalability, cost-effectiveness, and ease of handling to support growth 254
9.2.2.3 Flasks 257
9.2.2.3.1 Growing advancements in cell culture flasks to boost market 257
9.2.2.4 Multiwell plates 261
9.2.2.4.1 Increasing adoption of multiwell plates in high-throughput or high-content screening to aid growth 261
9.2.2.5 Petri dishes 264
9.2.2.5.1 Rising use of petri dishes as sterile containers to sustain growth 264
9.2.3 OTHER CONSUMABLES & ACCESSORIES 267
9.2.3.1 Reduced preparation time and equipment performance improvements to augment growth 267
9.3 EQUIPMENT 270
9.3.1 SUPPORTING EQUIPMENT 274
9.3.1.1 Filtration systems 277
9.3.1.1.1 Sterile filtration for contamination-controlled workflows to boost market 277
9.3.1.2 Cell counters 281
9.3.1.2.1 Growing adoption of automated cell counters to propel market 281
9.3.1.3 Carbon dioxide incubators 285
9.3.1.3.1 Increasing focus of research institutes on developing lab-scale incubators to drive market 285
9.3.1.4 Centrifuges 289
9.3.1.4.1 Increasing demand for bioproduction applications to drive adoption of centrifuges 289
9.3.1.5 Autoclaves 293
9.3.1.5.1 Reliance on single-use labware and equipment to affect demand for autoclaves 293
9.3.1.6 Microscopes 296
9.3.1.6.1 Rising adoption of live-cell imaging in 3D culture and stem cell models to support segment growth 296
9.3.1.7 Biosafety cabinets 300
9.3.1.7.1 Rising focus on contamination control and operator safety to support segment growth 300
9.3.1.8 Other supporting equipment 304
9.3.2 BIOREACTORS 307
9.3.2.1 Rising biologics and advanced therapy production to accelerate adoption of scalable bioreactor systems 307
9.3.3 STORAGE EQUIPMENT 311
9.3.3.1 Refrigerators & freezers 315
9.3.3.1.1 Increasing need for storage solutions to propel market 315
9.3.3.2 Cryostorage systems 318
9.3.3.2.1 Benefits of long-term preservation of cell cultures to support growth 318
10 CELL CULTURE MARKET, BY APPLICATION 322
10.1 INTRODUCTION 323
10.2 BIOPHARMACEUTICAL PRODUCTION 323
10.2.1 MONOCLONAL ANTIBODY PRODUCTION 327
10.2.1.1 Increasing approval and launch of monoclonal antibodies to amplify growth 327
10.2.2 VACCINE PRODUCTION 331
10.2.2.1 Rising incidence of infectious diseases to support growth 331
10.2.3 OTHER THERAPEUTIC PROTEIN PRODUCTION 335
10.3 DIAGNOSTICS 338
10.3.1 USE OF CULTURED CELLS IN CYTOGENETICS AND ASSAY VALIDATION TO SUPPORT SEGMENT GROWTH 338
10.4 TISSUE ENGINEERING & REGENERATIVE MEDICINE 342
10.4.1 CELL & GENE THERAPY 346
10.4.1.1 Rising approvals and manufacturing investments in advanced therapies to propel segment growth 346
10.4.2 OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS 350
10.5 DRUG SCREENING & DEVELOPMENT 353
10.5.1 ADOPTION OF HUMAN-RELEVANT 3D MODELS AND AUTOMATED SCREENING PLATFORMS TO PROPEL SEGMENT GROWTH 353
10.6 OTHER APPLICATIONS 357
11 CELL CULTURE MARKET, BY END USER 360
11.1 INTRODUCTION 361
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 361
11.2.1 INCREASING DEMAND FOR CULTURE CELL LINES FOR DRUG SCREENING AND R&D TO AID GROWTH 361
11.3 HOSPITALS & DIAGNOSTIC LABORATORIES 365
11.3.1 GROWING USE OF CELL CULTURE FOR CELLULAR PHYSIOLOGY, DISEASE MECHANISMS, AND DRUG RESPONSES TO BOOST MARKET 365
11.4 ACADEMIC & RESEARCH INSTITUTES 369
11.4.1 RISING FUNDING ACTIVITIES TO CONTRIBUTE TO GROWTH 369
11.5 OTHER END USERS 372
12 CELL CULTURE MARKET, BY REGION 376
12.1 INTRODUCTION 377
12.2 NORTH AMERICA 377
12.2.1 US 385
12.2.1.1 Strong biologics pipeline and domestic cell therapy manufacturing investments to bolster growth 385
12.2.2 CANADA 392
12.2.2.1 Increasing funding and investments for cell-based therapies to boost market 392
12.3 EUROPE 399
12.3.1 GERMANY 406
12.3.1.1 Biologics manufacturing strength and mRNA oncology investments to drive demand 406
12.3.2 UK 412
12.3.2.1 ATMP clinical infrastructure and government life sciences strategy to boost growth 412
12.3.3 FRANCE 418
12.3.3.1 Rising number of cell-based research projects to enhance growth 418
12.3.4 ITALY 424
12.3.4.1 Strong government support for R&D activities to spur growth 424
12.3.5 SPAIN 430
12.3.5.1 Rising biotechnology R&D investment to support cell-based research applications 430
12.3.6 REST OF EUROPE 436
12.4 ASIA PACIFIC 442
12.4.1 CHINA 450
12.4.1.1 Large-scale CRDMO activity and multinational cell therapy investments to accelerate growth 450
12.4.2 JAPAN 457
12.4.2.1 Rising government initiatives and increasing investments in biotech to intensify growth 457
12.4.3 INDIA 463
12.4.3.1 Favorable government support and expansion by key cell culture players to augment growth 463
12.4.4 SOUTH KOREA 469
12.4.4.1 Growing pharmaceutical sector to drive market 469
12.4.5 AUSTRALIA 475
12.4.5.1 Regenerative medicine funding and hospital-linked CAR-T manufacturing to support growth 475
12.4.6 REST OF ASIA PACIFIC 481
12.5 LATIN AMERICA 488
12.5.1 BRAZIL 495
12.5.1.1 Cell therapy partnerships and vaccine manufacturing capacity to strengthen regional leadership 495
12.5.2 MEXICO 501
12.5.2.1 Pharmaceutical manufacturing investments and clinical research capacity to support steady growth 501
12.5.3 REST OF LATIN AMERICA 507
12.6 MIDDLE EAST 514
12.6.1 GCC COUNTRIES 521
12.6.1.1 Saudi Arabia 527
12.6.1.1.1 Increasing focus on expansion to drive market 527
12.6.1.2 UAE 533
12.6.1.2.1 Increasing shift from importing to manufacturing pharmaceuticals to boost market 533
12.6.1.3 Rest of GCC Countries 539
12.6.2 REST OF MIDDLE EAST 545
12.7 AFRICA 551
12.7.1 RISING GRANTS AND FUNDING FOR CELL AND GENE THERAPY PRODUCTS TO FOSTER GROWTH 551
13 COMPETITIVE LANDSCAPE 558
13.1 OVERVIEW 558
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 558
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL CULTURE MARKET 558
13.3 REVENUE ANALYSIS, 2021–2025 560
13.4 MARKET SHARE ANALYSIS, 2025 561
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 563
13.5.1 STARS 564
13.5.2 EMERGING LEADERS 564
13.5.3 PERVASIVE PLAYERS 564
13.5.4 PARTICIPANTS 564
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 566
13.5.5.1 Company footprint 566
13.5.5.2 Regional footprint 566
13.5.5.3 Product footprint 567
13.5.5.4 Application footprint 568
13.5.5.5 End-user footprint 569
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 570
13.6.1 PROGRESSIVE COMPANIES 570
13.6.2 RESPONSIVE COMPANIES 570
13.6.3 DYNAMIC COMPANIES 570
13.6.4 STARTING BLOCKS 570
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 571
13.6.5.1 Detailed list of key startups/SMEs 571
13.6.5.2 Competitive benchmarking of key startups/SMEs 572
13.7 COMPANY VALUATION AND FINANCIAL METRICS 573
13.7.1 FINANCIAL METRICS 573
13.7.2 COMPANY VALUATION 573
13.8 BRAND/PRODUCT COMPARISON 574
13.9 COMPETITIVE SCENARIO 574
13.9.1 PRODUCT LAUNCHES 574
13.9.2 DEALS 575
13.9.3 EXPANSIONS 576
14 COMPANY PROFILES 578
14.1 INTRODUCTION 578
14.2 KEY PLAYERS 578
14.2.1 THERMO FISHER SCIENTIFIC INC. 578
14.2.1.1 Business overview 578
14.2.1.2 Products offered 579
14.2.1.3 Recent developments 592
14.2.1.3.1 Product launches 592
14.2.1.3.2 Deals 594
14.2.1.3.3 Expansions 595
14.2.1.4 MnM view 596
14.2.1.4.1 Right to win 596
14.2.1.4.2 Strategic choices 596
14.2.1.4.3 Weaknesses and competitive threats 596
14.2.2 DANAHER CORPORATION 597
14.2.2.1 Business overview 597
14.2.2.2 Products offered 598
14.2.2.3 Recent developments 608
14.2.2.3.1 Product launches 608
14.2.2.3.2 Deals 609
14.2.2.3.3 Expansions 610
14.2.2.3.4 Other developments 611
14.2.2.4 MnM view 611
14.2.2.4.1 Right to win 611
14.2.2.4.2 Strategic choices 612
14.2.2.4.3 Weaknesses and competitive threats 612
14.2.3 MERCK KGAA 613
14.2.3.1 Business overview 613
14.2.3.2 Products offered 614
14.2.3.3 Recent developments 621
14.2.3.3.1 Product launches 621
14.2.3.3.2 Deals 621
14.2.3.3.3 Expansions 622
14.2.3.4 MnM view 624
14.2.3.4.1 Right to win 624
14.2.3.4.2 Strategic choices 624
14.2.3.4.3 Weaknesses and competitive threats 624
14.2.4 SARTORIUS AG 625
14.2.4.1 Business overview 625
14.2.4.2 Products offered 626
14.2.4.3 Recent developments 634
14.2.4.3.1 Product launches 634
14.2.4.3.2 Deals 635
14.2.4.3.3 Expansions 637
14.2.4.4 MnM view 638
14.2.4.4.1 Right to win 638
14.2.4.4.2 Strategic choices 638
14.2.4.4.3 Weaknesses and competitive threats 639
14.2.5 CORNING INCORPORATED 640
14.2.5.1 Business overview 640
14.2.5.2 Products offered 641
14.2.5.3 Recent developments 650
14.2.5.3.1 Deals 650
14.2.6 FUJIFILM HOLDINGS CORPORATION 652
14.2.6.1 Business overview 652
14.2.6.2 Products offered 653
14.2.6.3 Recent developments 659
14.2.6.3.1 Product launches 659
14.2.6.3.2 Deals 660
14.2.6.3.3 Other developments 660
14.2.7 BD 661
14.2.7.1 Business overview 661
14.2.7.2 Product offered 662
14.2.7.3 Recent developments 664
14.2.7.3.1 Product Launches 664
14.2.7.3.2 Deals 664
14.2.7.3.3 Other developments 665
14.2.8 EPPENDORF SE 666
14.2.8.1 Business overview 666
14.2.8.2 Products offered 667
14.2.8.3 Recent developments 672
14.2.8.3.1 Product launches 672
14.2.8.3.2 Expansions 673
14.2.9 LONZA 674
14.2.9.1 Business overview 674
14.2.9.2 Products offered 675
14.2.9.3 Recent developments 678
14.2.9.3.1 Product launches 678
14.2.9.3.2 Deals 678
14.2.10 GETINGE 679
14.2.10.1 Business overview 679
14.2.10.2 Products offered 680
14.2.10.3 Recent developments 681
14.2.10.3.1 Product launches 681
14.2.10.3.2 Deals 682
14.2.11 AGILENT TECHNOLOGIES, INC. 683
14.2.11.1 Business overview 683
14.2.11.2 Products offered 684
14.2.11.3 Recent developments 686
14.2.11.3.1 Product launches 686
14.2.11.3.2 Deals 687
14.2.11.3.3 Expansions 687
14.2.12 HIMEDIA LABORATORIES 688
14.2.12.1 Business overview 688
14.2.12.2 Products offered 688
14.2.13 BIO-TECHNE 692
14.2.13.1 Business overview 692
14.2.13.2 Products offered 693
14.2.13.3 Recent developments 697
14.2.13.3.1 Product launches 697
14.2.13.3.2 Deals 697
14.2.13.3.3 Expansions 698
14.3 OTHER PLAYERS 699
14.3.1 MILTENYI BIOTEC 699
14.3.2 STEMCELL TECHNOLOGIES 701
14.3.3 SOLIDA BIOTECH GMBH 704
14.3.4 CAISSON LABS 705
14.3.5 PROMOCELL GMBH 706
14.3.6 INVIVOGEN 707
14.3.7 PAN-BIOTECH 708
14.3.8 CELLEXUS 709
14.3.9 MEISSNER FILTRATION PRODUCTS, INC. 710
14.3.10 ADOLF KÜHNER AG 712
14.3.11 ADVANCION CORPORATION 713
14.3.12 BIOSPHERIX LLC 714
15 RESEARCH METHODOLOGY 715
15.1 RESEARCH DATA 715
15.1.1 SECONDARY DATA 716
15.1.1.1 Key secondary sources 716
15.1.1.2 Key data from secondary research 716
15.1.2 PRIMARY DATA 717
15.1.2.1 Key primary participants 717
15.1.2.2 Breakdown of primary interviews 717
15.1.2.3 Key data from primary sources 717
15.2 MARKET SIZE ESTIMATION 718
15.2.1 GLOBAL CELL CULTURE MARKET ESTIMATION, 2025 718
15.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up) 718
15.2.1.2 Approach 2: Primary research 720
15.2.1.2.1 Key industry insights 720
15.2.1.3 Approach 3: MnM repository analysis 720
15.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025 721
15.3 MARKET GROWTH RATE PROJECTIONS 722
15.4 DATA TRIANGULATION 724
15.5 RESEARCH ASSUMPTIONS 725
15.6 RESEARCH LIMITATIONS AND RISK ASSESSMENT 726
16 APPENDIX 727
16.1 DISCUSSION GUIDE 727
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 731
16.3 CUSTOMIZATION OPTIONS 733
16.4 RELATED REPORTS 733
16.5 AUTHOR DETAILS 735

LIST OF TABLES

TABLE 1 CELL CULTURE MARKET: INCLUSIONS AND EXCLUSIONS 61
TABLE 2 CELL CULTURE MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 76
TABLE 3 NATIONAL INSTITUTES OF HEALTH FUNDING FOR STEM CELL-BASED RESEARCH, 2020–2024 (USD MILLION) 77
TABLE 4 FUNDING INVESTMENTS IN CELL & GENE THERAPY, 2023–2026 77
TABLE 5 COMMERCIALLY SPONSORED MONOCLONAL ANTIBODY THERAPEUTICS GRANTED FIRST APPROVAL IN 2025 79
TABLE 6 ASIA PACIFIC: PRIVATE ROUNDS IN BIOTECH COMPANIES FOCUSED ON HEALTHCARE, 2024–2026 86
TABLE 7 COMPARISON OF SINGLE-USE BIOPROCESSING SYSTEM DISPOSAL OPTIONS 89
TABLE 8 CELL CULTURE MARKET: IMPACT OF PORTER’S FIVE FORCES 92
TABLE 9 CELL CULTURE MARKET: ROLE IN ECOSYSTEM 98
TABLE 10 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT,
2023–2025 (USD) 99
TABLE 11 AVERAGE SELLING PRICE TREND OF CELL CULTURE PRODUCTS, BY REGION, 2023–2025 (USD) 101
TABLE 12 IMPORT DATA FOR HS CODE 382100, 2021–2025 (USD THOUSAND) 103
TABLE 13 IMPORT DATA FOR HS CODE 382100, 2021–2025 (TONS) 103
TABLE 14 EXPORT DATA FOR HS CODE 382100, 2021–2025 (USD THOUSAND) 104
TABLE 15 EXPORT DATA FOR HS CODE 382100, 2021–2025 (TONS) 105
TABLE 16 CELL CULTURE MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 105
TABLE 17 US ADJUSTED RECIPROCAL TARIFF RATES 109
TABLE 18 IMPACT ON END-USE APPLICATIONS OF CELL-BASED ASSAY PRODUCTS 112
TABLE 19 ADVANTAGES OF SINGLE-USE OVER STAINLESS-STEEL BIOREACTORS 115
TABLE 20 ADVANTAGES AND DISADVANTAGES OF MICROFLUIDIC CELL CULTURE 117
TABLE 21 CELL CULTURE MARKET: INDICATIVE LIST OF PATENTS, 2026 120
TABLE 22 CASE STUDIES OF AI IMPLEMENTATION IN CELL CULTURE MARKET 124
TABLE 23 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN CELL CULTURE 125
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 126
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 126
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 128
TABLE 27 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 128
TABLE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 135
TABLE 29 KEY BUYING CRITERIA, BY END USER 136
TABLE 30 CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 139
TABLE 31 CELL CULTURE CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 139
TABLE 32 CELL CULTURE CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 140
TABLE 33 NORTH AMERICA: CELL CULTURE CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 140
TABLE 34 EUROPE: CELL CULTURE CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 141
TABLE 35 ASIA PACIFIC: CELL CULTURE CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 141
TABLE 36 LATIN AMERICA: CELL CULTURE CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 37 MIDDLE EAST: CELL CULTURE CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 142
TABLE 38 GCC COUNTRIES: CELL CULTURE CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 39 CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 143
TABLE 40 CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 144
TABLE 41 NORTH AMERICA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 42 EUROPE: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 43 ASIA PACIFIC: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 44 LATIN AMERICA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 45 MIDDLE EAST: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 146
TABLE 46 GCC COUNTRIES: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 47 CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 147
TABLE 48 CELL CULTURE MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 148
TABLE 49 NORTH AMERICA: CELL CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 148
TABLE 50 EUROPE: CELL CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 51 ASIA PACIFIC: CELL CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 52 LATIN AMERICA: CELL CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 53 MIDDLE EAST: CELL CULTURE MEDIA MARKET, BY REGION,
2024–2031 (USD MILLION) 150
TABLE 54 GCC COUNTRIES: CELL CULTURE MEDIA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 55 CELL CULTURE MEDIA MARKET, BY REGION, 2024–2031 (MILLION LITERS) 151
TABLE 56 SERUM-FREE MEDIA OFFERED BY KEY MARKET PLAYERS 152
TABLE 57 CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 152
TABLE 58 CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY REGION,
2024–2031 (USD MILLION) 153
TABLE 59 NORTH AMERICA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 60 EUROPE: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 61 ASIA PACIFIC: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 62 LATIN AMERICA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 63 MIDDLE EAST: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY REGION, 2024–2031 (USD MILLION) 155
TABLE 64 GCC COUNTRIES: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 65 CELL CULTURE MARKET FOR CHO MEDIA, BY REGION, 2024–2031 (USD MILLION) 156
TABLE 66 NORTH AMERICA: CELL CULTURE MARKET FOR CHO MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 67 EUROPE: CELL CULTURE MARKET FOR CHO MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 68 ASIA PACIFIC: CELL CULTURE MARKET FOR CHO MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 158
TABLE 69 LATIN AMERICA: CELL CULTURE MARKET FOR CHO MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 158
TABLE 70 MIDDLE EAST: CELL CULTURE MARKET FOR CHO MEDIA, BY REGION,
2024–2031 (USD MILLION) 158
TABLE 71 GCC COUNTRIES: CELL CULTURE MARKET FOR CHO MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 159
TABLE 72 CELL CULTURE MARKET FOR HEK 293 MEDIA, BY REGION,
2024–2031 (USD MILLION) 160
TABLE 73 NORTH AMERICA: CELL CULTURE MARKET FOR HEK 293 MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 74 EUROPE: CELL CULTURE MARKET FOR HEK 293 MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 161
TABLE 75 ASIA PACIFIC: CELL CULTURE MARKET FOR HEK 293 MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 161
TABLE 76 LATIN AMERICA: CELL CULTURE MARKET FOR HEK 293 MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 77 MIDDLE EAST: CELL CULTURE MARKET FOR HEK 293 MEDIA, BY REGION,
2024–2031 (USD MILLION) 162
TABLE 78 GCC COUNTRIES: CELL CULTURE MARKET FOR HEK 293 MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 79 CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA, BY REGION,
2024–2031 (USD MILLION) 163
TABLE 80 NORTH AMERICA: CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 81 EUROPE: CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 82 ASIA PACIFIC: CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 83 LATIN AMERICA: CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 84 MIDDLE EAST: CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA,
BY REGION, 2024–2031 (USD MILLION) 165
TABLE 85 GCC COUNTRIES: CELL CULTURE MARKET FOR SERUM-FREE STEM CELL MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 86 CELL CULTURE MARKET FOR VERO CELL MEDIA, BY REGION,
2024–2031 (USD MILLION) 167
TABLE 87 NORTH AMERICA: CELL CULTURE MARKET FOR VERO CELL MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 88 EUROPE: CELL CULTURE MARKET FOR VERO CELL MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 168
TABLE 89 ASIA PACIFIC: CELL CULTURE MARKET FOR VERO CELL MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 90 LATIN AMERICA: CELL CULTURE MARKET FOR VERO CELL MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 91 MIDDLE EAST: CELL CULTURE MARKET FOR VERO CELL MEDIA, BY REGION, 2024–2031 (USD MILLION) 169
TABLE 92 GCC COUNTRIES: CELL CULTURE MARKET FOR VERO CELL MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 93 CELL CULTURE MARKET FOR BHK MEDIA, BY REGION, 2024–2031 (USD MILLION) 170
TABLE 94 NORTH AMERICA: CELL CULTURE MARKET FOR BHK MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 171
TABLE 95 EUROPE: CELL CULTURE MARKET FOR BHK MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 171
TABLE 96 ASIA PACIFIC: CELL CULTURE MARKET FOR BHK MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 172
TABLE 97 LATIN AMERICA: CELL CULTURE MARKET FOR BHK MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 172
TABLE 98 MIDDLE EAST: CELL CULTURE MARKET FOR BHK MEDIA, BY REGION,
2024–2031 (USD MILLION) 172
TABLE 99 GCC COUNTRIES: CELL CULTURE MARKET FOR BHK MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 173
TABLE 100 CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA, BY REGION,
2024–2031 (USD MILLION) 173
TABLE 101 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 102 EUROPE: CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 103 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 104 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 105 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA,
BY REGION, 2024–2031 (USD MILLION) 175
TABLE 106 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER SERUM-FREE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 107 CLASSICAL MEDIA & SALTS OFFERED BY KEY MARKET PLAYERS 176
TABLE 108 CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS, BY REGION,
2024–2031 (USD MILLION) 177
TABLE 109 NORTH AMERICA: CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 110 EUROPE: CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 111 ASIA PACIFIC: CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS,
BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 112 LATIN AMERICA: CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS,
BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 113 MIDDLE EAST: CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS,
BY REGION, 2024–2031 (USD MILLION) 179
TABLE 114 GCC COUNTRIES: CELL CULTURE MARKET FOR CLASSICAL MEDIA & SALTS,
BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 115 STEM CELL CULTURE MEDIA OFFERED BY KEY MARKET PLAYERS 180
TABLE 116 CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA, BY REGION,
2024–2031 (USD MILLION) 180
TABLE 117 NORTH AMERICA: CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 118 EUROPE: CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 119 ASIA PACIFIC: CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 120 LATIN AMERICA: CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 121 MIDDLE EAST: CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA,
BY REGION, 2024–2031 (USD MILLION) 182
TABLE 122 GCC COUNTRIES: CELL CULTURE MARKET FOR STEM CELL CULTURE MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 123 CHEMICALLY-DEFINED MEDIA OFFERED BY KEY MARKET PLAYERS 184
TABLE 124 CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA, BY REGION,
2024–2031 (USD MILLION) 184
TABLE 125 NORTH AMERICA: CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 126 EUROPE: CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 127 ASIA PACIFIC: CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 128 LATIN AMERICA: CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 129 MIDDLE EAST: CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA,
BY REGION, 2024–2031 (USD MILLION) 186
TABLE 130 GCC COUNTRIES: CELL CULTURE MARKET FOR CHEMICALLY-DEFINED MEDIA,
BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 131 SPECIALTY MEDIA OFFERED BY KEY MARKET PLAYERS 187
TABLE 132 CELL CULTURE MARKET FOR SPECIALTY MEDIA, BY REGION,
2024–2031 (USD MILLION) 188
TABLE 133 NORTH AMERICA: CELL CULTURE MARKET FOR SPECIALTY MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 134 EUROPE: CELL CULTURE MARKET FOR SPECIALTY MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 189
TABLE 135 ASIA PACIFIC: CELL CULTURE MARKET FOR SPECIALTY MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 136 LATIN AMERICA: CELL CULTURE MARKET FOR SPECIALTY ME
DIA, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 137 MIDDLE EAST: CELL CULTURE MARKET FOR SPECIALTY MEDIA, BY REGION, 2024–2031 (USD MILLION) 190
TABLE 138 GCC COUNTRIES: CELL CULTURE MARKET FOR SPECIALTY MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 139 OTHER MEDIA OFFERED BY KEY MARKET PLAYERS 191
TABLE 140 CELL CULTURE MARKET FOR OTHER MEDIA, BY REGION,
2024–2031 (USD MILLION) 192
TABLE 141 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 142 EUROPE: CELL CULTURE MARKET FOR OTHER MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 193
TABLE 143 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 193
TABLE 144 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER MEDIA, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 145 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER MEDIA, BY REGION,
2024–2031 (USD MILLION) 194
TABLE 146 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER MEDIA, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 147 CELL CULTURE REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 148 CELL CULTURE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 196
TABLE 149 NORTH AMERICA: CELL CULTURE REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 196
TABLE 150 EUROPE: CELL CULTURE REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 151 ASIA PACIFIC: CELL CULTURE REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 152 LATIN AMERICA: CELL CULTURE REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 198
TABLE 153 MIDDLE EAST: CELL CULTURE REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 198
TABLE 154 GCC COUNTRIES: CELL CULTURE REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 198
TABLE 155 CELL CULTURE MARKET FOR GROWTH FACTORS, BY REGION,
2024–2031 (USD MILLION) 199
TABLE 156 NORTH AMERICA: CELL CULTURE MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 157 EUROPE: CELL CULTURE MARKET FOR GROWTH FACTORS, BY COUNTRY,
2024–2031 (USD MILLION) 200
TABLE 158 ASIA PACIFIC: CELL CULTURE MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 159 LATIN AMERICA: CELL CULTURE MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 160 MIDDLE EAST: CELL CULTURE MARKET FOR GROWTH FACTORS, BY REGION, 2024–2031 (USD MILLION) 201
TABLE 161 GCC COUNTRIES: CELL CULTURE MARKET FOR GROWTH FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 162 CELL CULTURE MARKET FOR SUPPLEMENTS, BY REGION,
2024–2031 (USD MILLION) 203
TABLE 163 NORTH AMERICA: CELL CULTURE MARKET FOR SUPPLEMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 164 EUROPE: CELL CULTURE MARKET FOR SUPPLEMENTS, BY COUNTRY,
2024–2031 (USD MILLION) 204
TABLE 165 ASIA PACIFIC: CELL CULTURE MARKET FOR SUPPLEMENTS, BY COUNTRY,
2024–2031 (USD MILLION) 204
TABLE 166 LATIN AMERICA: CELL CULTURE MARKET FOR SUPPLEMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 167 MIDDLE EAST: CELL CULTURE MARKET FOR SUPPLEMENTS, BY REGION,
2024–2031 (USD MILLION) 205
TABLE 168 GCC COUNTRIES: CELL CULTURE MARKET FOR SUPPLEMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 169 CELL CULTURE MARKET FOR BUFFERS & CHEMICALS, BY REGION,
2024–2031 (USD MILLION) 206
TABLE 170 NORTH AMERICA: CELL CULTURE MARKET FOR BUFFERS & CHEMICALS,
BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 171 EUROPE: CELL CULTURE MARKET FOR BUFFERS & CHEMICALS, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 172 ASIA PACIFIC: CELL CULTURE MARKET FOR BUFFERS & CHEMICALS, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 173 LATIN AMERICA: CELL CULTURE MARKET FOR BUFFERS & CHEMICALS,
BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 174 MIDDLE EAST: CELL CULTURE MARKET FOR BUFFERS & CHEMICALS, BY REGION, 2024–2031 (USD MILLION) 208
TABLE 175 GCC COUNTRIES: CELL CULTURE MARKET FOR BUFFERS & CHEMICALS,
BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 176 CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS, BY REGION,
2024–2031 (USD MILLION) 210
TABLE 177 NORTH AMERICA: CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 178 EUROPE: CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 179 ASIA PACIFIC: CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 180 LATIN AMERICA: CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 181 MIDDLE EAST: CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS,
BY REGION, 2024–2031 (USD MILLION) 212
TABLE 182 GCC COUNTRIES: CELL CULTURE MARKET FOR CELL DISSOCIATION REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 183 CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS, BY REGION,
2024–2031 (USD MILLION) 213
TABLE 184 NORTH AMERICA: CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 185 EUROPE: CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 186 ASIA PACIFIC: CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 187 LATIN AMERICA: CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 188 MIDDLE EAST: CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS,
BY REGION, 2024–2031 (USD MILLION) 215
TABLE 189 GCC COUNTRIES: CELL CULTURE MARKET FOR BALANCED SALT SOLUTIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 190 CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS, BY REGION, 2024–2031 (USD MILLION) 217
TABLE 191 NORTH AMERICA: CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 192 EUROPE: CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS,
BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 193 ASIA PACIFIC: CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS,
BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 194 LATIN AMERICA: CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 195 MIDDLE EAST: CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS,
BY REGION, 2024–2031 (USD MILLION) 219
TABLE 196 GCC COUNTRIES: CELL CULTURE MARKET FOR ATTACHMENT & MATRIX FACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 197 CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS, BY REGION,
2024–2031 (USD MILLION) 220
TABLE 198 NORTH AMERICA: CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 199 EUROPE: CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 200 ASIA PACIFIC: CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 201 LATIN AMERICA: CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 202 MIDDLE EAST: CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS,
BY REGION, 2024–2031 (USD MILLION) 222
TABLE 203 GCC COUNTRIES: CELL CULTURE MARKET FOR ANTIBIOTICS/ANTIMYCOTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 204 CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS, BY REGION,
2024–2031 (USD MILLION) 223
TABLE 205 NORTH AMERICA: CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 206 EUROPE: CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 207 ASIA PACIFIC: CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 208 LATIN AMERICA: CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 209 MIDDLE EAST: CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS,
BY REGION, 2024–2031 (USD MILLION) 225
TABLE 210 GCC COUNTRIES: CELL CULTURE MARKET FOR CRYOPROTECTIVE REAGENTS,
BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 211 CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS, BY REGION, 2024–2031 (USD MILLION) 227
TABLE 212 NORTH AMERICA: CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 213 EUROPE: CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS,
BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 214 ASIA PACIFIC: CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS,
BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 215 LATIN AMERICA: CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS, BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 216 MIDDLE EAST: CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS,
BY REGION, 2024–2031 (USD MILLION) 229
TABLE 217 GCC COUNTRIES: CELL CULTURE MARKET FOR CONTAMINATION DETECTION KITS, BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 218 CELL CULTURE MARKET FOR OTHER REAGENTS, BY REGION,
2024–2031 (USD MILLION) 230
TABLE 219 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 220 EUROPE: CELL CULTURE MARKET FOR OTHER REAGENTS, BY COUNTRY,
2024–2031 (USD MILLION) 231
TABLE 221 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 222 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 223 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER REAGENTS, BY REGION, 2024–2031 (USD MILLION) 232
TABLE 224 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 225 CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 226 CELL CULTURE SERA MARKET, BY REGION, 2024–2031 (USD MILLION) 234
TABLE 227 NORTH AMERICA: CELL CULTURE SERA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 234
TABLE 228 EUROPE: CELL CULTURE SERA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 229 ASIA PACIFIC: CELL CULTURE SERA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 235
TABLE 230 LATIN AMERICA: CELL CULTURE SERA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 235
TABLE 231 MIDDLE EAST: CELL CULTURE SERA MARKET, BY REGION,
2024–2031 (USD MILLION) 236
TABLE 232 GCC COUNTRIES: CELL CULTURE SERA MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 236
TABLE 233 CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY REGION,
2024–2031 (USD MILLION) 237
TABLE 234 NORTH AMERICA: CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 235 EUROPE: CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY COUNTRY,
2024–2031 (USD MILLION) 238
TABLE 236 ASIA PACIFIC: CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 237 LATIN AMERICA: CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 238 MIDDLE EAST: CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY REGION, 2024–2031 (USD MILLION) 239
TABLE 239 GCC COUNTRIES: CELL CULTURE MEDIA FOR FETAL BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 240 CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY REGION,
2024–2031 (USD MILLION) 240
TABLE 241 NORTH AMERICA: CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 242 EUROPE: CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY COUNTRY,
2024–2031 (USD MILLION) 241
TABLE 243 ASIA PACIFIC: CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 244 LATIN AMERICA: CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 245 MIDDLE EAST: CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY REGION, 2024–2031 (USD MILLION) 242
TABLE 246 GCC COUNTRIES: CELL CULTURE MEDIA FOR ADULT BOVINE SERA, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 247 CELL CULTURE MARKET FOR OTHER ANIMAL SERA, BY REGION,
2024–2031 (USD MILLION) 244
TABLE 248 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER ANIMAL SERA,
BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 249 EUROPE: CELL CULTURE MARKET FOR OTHER ANIMAL SERA, BY COUNTRY,
2024–2031 (USD MILLION) 245
TABLE 250 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER ANIMAL SERA, BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 251 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER ANIMAL SERA, BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 252 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER ANIMAL SERA, BY REGION, 2024–2031 (USD MILLION) 246
TABLE 253 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER ANIMAL SERA,
BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 254 CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 255 CELL CULTURE VESSELS MARKET, BY REGION, 2024–2031 (USD MILLION) 247
TABLE 256 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 248
TABLE 257 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 248
TABLE 258 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 249
TABLE 259 LATIN AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 249
TABLE 260 MIDDLE EAST: CELL CULTURE VESSELS MARKET, BY REGION,
2024–2031 (USD MILLION) 249
TABLE 261 GCC COUNTRIES: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 250
TABLE 262 CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS, BY REGION, 2024–2031 (USD MILLION) 251
TABLE 263 NORTH AMERICA: CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS, BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 264 EUROPE: CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS,
BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 265 ASIA PACIFIC: CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS, BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 266 LATIN AMERICA: CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 267 MIDDLE EAST: CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS, BY REGION, 2024–2031 (USD MILLION) 253
TABLE 268 GCC COUNTRIES: CELL CULTURE MARKET FOR CELL FACTORY SYSTEMS/CELL STACKS, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 269 CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES, BY REGION,
2024–2031 (USD MILLION) 254
TABLE 270 NORTH AMERICA: CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES,
BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 271 EUROPE: CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES, BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 272 ASIA PACIFIC: CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 273 LATIN AMERICA: CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES,
BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 274 MIDDLE EAST: CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES, BY REGION, 2024–2031 (USD MILLION) 256
TABLE 275 GCC COUNTRIES: CELL CULTURE MARKET FOR ROLLER/ROUX BOTTLES,
BY COUNTRY, 2024–2031 (USD MILLION) 257
TABLE 276 CELL CULTURE MARKET FOR FLASKS, BY REGION, 2024–2031 (USD MILLION) 258
TABLE 277 NORTH AMERICA: CELL CULTURE MARKET FOR FLASKS, BY COUNTRY,
2024–2031 (USD MILLION) 258
TABLE 278 EUROPE: CELL CULTURE MARKET FOR FLASKS, BY COUNTRY,
2024–2031 (USD MILLION) 259
TABLE 279 ASIA PACIFIC: CELL CULTURE MARKET FOR FLASKS, BY COUNTRY,
2024–2031 (USD MILLION) 259
TABLE 280 LATIN AMERICA: CELL CULTURE MARKET FOR FLASKS, BY COUNTRY,
2024–2031 (USD MILLION) 260
TABLE 281 MIDDLE EAST: CELL CULTURE MARKET FOR FLASKS, BY REGION,
2024–2031 (USD MILLION) 260
TABLE 282 GCC COUNTRIES: CELL CULTURE MARKET FOR FLASKS, BY COUNTRY,
2024–2031 (USD MILLION) 260
TABLE 283 CELL CULTURE MARKET FOR MULTIWELL PLATES, BY REGION,
2024–2031 (USD MILLION) 261
TABLE 284 NORTH AMERICA: CELL CULTURE MARKET FOR MULTIWELL PLATES, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 285 EUROPE: CELL CULTURE MARKET FOR MULTIWELL PLATES, BY COUNTRY,
2024–2031 (USD MILLION) 262
TABLE 286 ASIA PACIFIC: CELL CULTURE MARKET FOR MULTIWELL PLATES, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 287 LATIN AMERICA: CELL CULTURE MARKET FOR MULTIWELL PLATES, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 288 MIDDLE EAST: CELL CULTURE MARKET FOR MULTIWELL PLATES, BY REGION, 2024–2031 (USD MILLION) 263
TABLE 289 GCC COUNTRIES: CELL CULTURE MARKET FOR MULTIWELL PLATES, BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 290 CELL CULTURE MARKET FOR PETRI DISHES, BY REGION,
2024–2031 (USD MILLION) 264
TABLE 291 NORTH AMERICA: CELL CULTURE MARKET FOR PETRI DISHES, BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 292 EUROPE: CELL CULTURE MARKET FOR PETRI DISHES, BY COUNTRY,
2024–2031 (USD MILLION) 265
TABLE 293 ASIA PACIFIC: CELL CULTURE MARKET FOR PETRI DISHES, BY COUNTRY,
2024–2031 (USD MILLION) 266
TABLE 294 LATIN AMERICA: CELL CULTURE MARKET FOR PETRI DISHES, BY COUNTRY,
2024–2031 (USD MILLION) 266
TABLE 295 MIDDLE EAST: CELL CULTURE MARKET FOR PETRI DISHES, BY REGION,
2024–2031 (USD MILLION) 266
TABLE 296 GCC COUNTRIES: CELL CULTURE MARKET FOR PETRI DISHES, BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 297 CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION) 267
TABLE 298 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 299 EUROPE: CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 300 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 301 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 302 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION) 269
TABLE 303 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER CONSUMABLES & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 270
TABLE 304 CELL CULTURE EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 305 CELL CULTURE EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 271
TABLE 306 NORTH AMERICA: CELL CULTURE EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 271
TABLE 307 EUROPE: CELL CULTURE EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 272
TABLE 308 ASIA PACIFIC: CELL CULTURE EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 272
TABLE 309 LATIN AMERICA: CELL CULTURE EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 273
TABLE 310 MIDDLE EAST: CELL CULTURE EQUIPMENT MARKET, BY REGION,
2024–2031 (USD MILLION) 273
TABLE 311 GCC COUNTRIES: CELL CULTURE EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 273
TABLE 312 CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 274
TABLE 313 CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY REGION,
2024–2031 (USD MILLION) 274
TABLE 314 NORTH AMERICA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 315 EUROPE: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 316 ASIA PACIFIC: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 276
TABLE 317 LATIN AMERICA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 276
TABLE 318 MIDDLE EAST: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT,
BY REGION, 2024–2031 (USD MILLION) 276
TABLE 319 GCC COUNTRIES: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 320 FILTRATION SYSTEMS OFFERED BY KEY PLAYERS 278
TABLE 321 CELL CULTURE MARKET FOR FILTRATION SYSTEMS, BY REGION,
2024–2031 (USD MILLION) 278
TABLE 322 NORTH AMERICA: CELL CULTURE MARKET FOR FILTRATION SYSTEMS,
BY COUNTRY, 2024–2031 (USD MILLION) 278
TABLE 323 EUROPE: CELL CULTURE MARKET FOR FILTRATION SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 324 ASIA PACIFIC: CELL CULTURE MARKET FOR FILTRATION SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 325 LATIN AMERICA: CELL CULTURE MARKET FOR FILTRATION SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 326 MIDDLE EAST: CELL CULTURE MARKET FOR FILTRATION SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 280
TABLE 327 GCC COUNTRIES: CELL CULTURE MARKET FOR FILTRATION SYSTEMS,
BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 328 CELL COUNTERS OFFERED BY KEY MARKET PLAYERS 281
TABLE 329 CELL CULTURE MARKET FOR CELL COUNTERS, BY REGION,
2024–2031 (USD MILLION) 282
TABLE 330 NORTH AMERICA: CELL CULTURE MARKET FOR CELL COUNTERS, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 331 EUROPE: CELL CULTURE MARKET FOR CELL COUNTERS, BY COUNTRY,
2024–2031 (USD MILLION) 283
TABLE 332 ASIA PACIFIC: CELL CULTURE MARKET FOR CELL COUNTERS, BY COUNTRY,
2024–2031 (USD MILLION) 283
TABLE 333 LATIN AMERICA: CELL CULTURE MARKET FOR CELL COUNTERS, BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 334 MIDDLE EAST: CELL CULTURE MARKET FOR CELL COUNTERS, BY REGION,
2024–2031 (USD MILLION) 284
TABLE 335 GCC COUNTRIES: CELL CULTURE MARKET FOR CELL COUNTERS, BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 336 CARBON DIOXIDE INCUBATORS OFFERED BY KEY MARKET PLAYERS 285
TABLE 337 CELL CULTURE MARKET FOR CARBON DIOXIDE INCUBATORS, BY REGION,
2024–2031 (USD MILLION) 286
TABLE 338 NORTH AMERICA: CELL CULTURE MARKET FOR CARBON DIOXIDE INCUBATORS, BY COUNTRY, 2024–2031 (USD MILLION) 286
TABLE 339 EUROPE: CELL CULTURE MARKET FOR CARBON DIOXIDE INCUBATORS,
BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 340 ASIA PACIFIC: CELL CULTURE MARKET FOR CARBON DIOXIDE INCUBATORS,
BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 341 LATIN AMERICA: CELL CULTURE MARKET FOR CARBON DIOXIDE INCUBATORS,
BY COUNTRY, 2024–2031 (USD MILLION) 288
TABLE 342 MIDDLE EAST: CELL CULTURE MARKET FOR CARBON DIOXIDE INCUBATORS,
BY REGION, 2024–2031 (USD MILLION) 288
TABLE 343 GCC COUNTRIES: CELL CULTURE MARKET FOR CARBON DIOXIDE INCUBATORS,
BY COUNTRY, 2024–2031 (USD MILLION) 288
TABLE 344 CENTRIFUGES OFFERED BY KEY MARKET PLAYERS 289
TABLE 345 CELL CULTURE MARKET FOR CENTRIFUGES, BY REGION,
2024–2031 (USD MILLION) 290
TABLE 346 NORTH AMERICA: CELL CULTURE MARKET FOR CENTRIFUGES, BY COUNTRY, 2024–2031 (USD MILLION) 290
TABLE 347 EUROPE: CELL CULTURE MARKET FOR CENTRIFUGES, BY COUNTRY,
2024–2031 (USD MILLION) 291
TABLE 348 ASIA PACIFIC: CELL CULTURE MARKET FOR CENTRIFUGES, BY COUNTRY,
2024–2031 (USD MILLION) 291
TABLE 349 LATIN AMERICA: CELL CULTURE MARKET FOR CENTRIFUGES, BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 350 MIDDLE EAST: CELL CULTURE MARKET FOR CENTRIFUGES, BY REGION,
2024–2031 (USD MILLION) 292
TABLE 351 GCC COUNTRIES: CELL CULTURE MARKET FOR CENTRIFUGES, BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 352 CELL CULTURE MARKET FOR AUTOCLAVES, BY REGION,
2024–2031 (USD MILLION) 293
TABLE 353 NORTH AMERICA: CELL CULTURE MARKET FOR AUTOCLAVES, BY COUNTRY, 2024–2031 (USD MILLION) 294
TABLE 354 EUROPE: CELL CULTURE MARKET FOR AUTOCLAVES, BY COUNTRY,
2024–2031 (USD MILLION) 294
TABLE 355 ASIA PACIFIC: CELL CULTURE MARKET FOR AUTOCLAVES, BY COUNTRY,
2024–2031 (USD MILLION) 295
TABLE 356 LATIN AMERICA: CELL CULTURE MARKET FOR AUTOCLAVES, BY COUNTRY,
2024–2031 (USD MILLION) 295
TABLE 357 MIDDLE EAST: CELL CULTURE MARKET FOR AUTOCLAVES, BY REGION,
2024–2031 (USD MILLION) 295
TABLE 358 GCC COUNTRIES: CELL CULTURE MARKET FOR AUTOCLAVES, BY COUNTRY,
2024–2031 (USD MILLION) 296
TABLE 359 CELL CULTURE MARKET FOR MICROSCOPES, BY REGION,
2024–2031 (USD MILLION) 297
TABLE 360 NORTH AMERICA: CELL CULTURE MARKET FOR MICROSCOPES, BY COUNTRY, 2024–2031 (USD MILLION) 297
TABLE 361 EUROPE: CELL CULTURE MARKET FOR MICROSCOPES, BY COUNTRY,
2024–2031 (USD MILLION) 298
TABLE 362 ASIA PACIFIC: CELL CULTURE MARKET FOR MICROSCOPES, BY COUNTRY,
2024–2031 (USD MILLION) 298
TABLE 363 LATIN AMERICA: CELL CULTURE MARKET FOR MICROSCOPES, BY COUNTRY, 2024–2031 (USD MILLION) 299
TABLE 364 MIDDLE EAST: CELL CULTURE MARKET FOR MICROSCOPES, BY REGION,
2024–2031 (USD MILLION) 299
TABLE 365 GCC COUNTRIES: CELL CULTURE MARKET FOR MICROSCOPES, BY COUNTRY, 2024–2031 (USD MILLION) 299
TABLE 366 BIOSAFETY CABINETS OFFERED BY KEY MARKET PLAYERS 300
TABLE 367 CELL CULTURE MARKET FOR BIOSAFETY CABINETS, BY REGION,
2024–2031 (USD MILLION) 301
TABLE 368 NORTH AMERICA: CELL CULTURE MARKET FOR BIOSAFETY CABINETS,
BY COUNTRY, 2024–2031 (USD MILLION) 301
TABLE 369 EUROPE: CELL CULTURE MARKET FOR BIOSAFETY CABINETS, BY COUNTRY, 2024–2031 (USD MILLION) 302
TABLE 370 ASIA PACIFIC: CELL CULTURE MARKET FOR BIOSAFETY CABINETS, BY COUNTRY, 2024–2031 (USD MILLION) 302
TABLE 371 LATIN AMERICA: CELL CULTURE MARKET FOR BIOSAFETY CABINETS, BY COUNTRY, 2024–2031 (USD MILLION) 303
TABLE 372 MIDDLE EAST: CELL CULTURE MARKET FOR BIOSAFETY CABINETS, BY REGION, 2024–2031 (USD MILLION) 303
TABLE 373 GCC COUNTRIES: CELL CULTURE MARKET FOR BIOSAFETY CABINETS,
BY COUNTRY, 2024–2031 (USD MILLION) 303
TABLE 374 OTHER SUPPORTING EQUIPMENT OFFERED BY KEY MARKET PLAYERS 304
TABLE 375 CELL CULTURE MARKET FOR OTHER SUPPORTING EQUIPMENT, BY REGION, 2024–2031 (USD MILLION) 304
TABLE 376 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER SUPPORTING EQUIPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 305
TABLE 377 EUROPE: CELL CULTURE MARKET FOR OTHER SUPPORTING EQUIPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 305
TABLE 378 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER SUPPORTING EQUIPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 306
TABLE 379 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER SUPPORTING EQUIPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 306
TABLE 380 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER SUPPORTING EQUIPMENT,
BY REGION, 2024–2031 (USD MILLION) 306
TABLE 381 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER SUPPORTING EQUIPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 307
TABLE 382 COMMERCIALLY AVAILABLE BIOREACTORS BY KEY PLAYERS 308
TABLE 383 CELL CULTURE MARKET FOR BIOREACTORS, BY REGION,
2024–2031 (USD MILLION) 308
TABLE 384 NORTH AMERICA: CELL CULTURE MARKET FOR BIOREACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 309
TABLE 385 EUROPE: CELL CULTURE MARKET FOR BIOREACTORS, BY COUNTRY,
2024–2031 (USD MILLION) 309
TABLE 386 ASIA PACIFIC: CELL CULTURE MARKET FOR BIOREACTORS, BY COUNTRY,
2024–2031 (USD MILLION) 310
TABLE 387 LATIN AMERICA: CELL CULTURE MARKET FOR BIOREACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 310
TABLE 388 MIDDLE EAST: CELL CULTURE MARKET FOR BIOREACTORS, BY REGION,
2024–2031 (USD MILLION) 310
TABLE 389 GCC COUNTRIES: CELL CULTURE MARKET FOR BIOREACTORS, BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 390 CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 311
TABLE 391 CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY REGION,
2024–2031 (USD MILLION) 312
TABLE 392 NORTH AMERICA: CELL CULTURE MARKET FOR STORAGE EQUIPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 312
TABLE 393 EUROPE: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 313
TABLE 394 ASIA PACIFIC: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 313
TABLE 395 LATIN AMERICA: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 314
TABLE 396 MIDDLE EAST: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY REGION, 2024–2031 (USD MILLION) 314
TABLE 397 GCC COUNTRIES: CELL CULTURE MARKET FOR STORAGE EQUIPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 314
TABLE 398 CELL CULTURE MARKET FOR REFRIGERATORS & FREEZERS, BY REGION,
2024–2031 (USD MILLION) 315
TABLE 399 NORTH AMERICA: CELL CULTURE MARKET FOR REFRIGERATORS & FREEZERS,
BY COUNTRY, 2024–2031 (USD MILLION) 316
TABLE 400 EUROPE: CELL CULTURE MARKET FOR REFRIGERATORS & FREEZERS,
BY COUNTRY, 2024–2031 (USD MILLION) 316
TABLE 401 ASIA PACIFIC: CELL CULTURE MARKET FOR REFRIGERATORS & FREEZERS,
BY COUNTRY, 2024–2031 (USD MILLION) 317
TABLE 402 LATIN AMERICA: CELL CULTURE MARKET FOR REFRIGERATORS & FREEZERS,
BY COUNTRY, 2024–2031 (USD MILLION) 317
TABLE 403 MIDDLE EAST: CELL CULTURE MARKET FOR REFRIGERATORS & FREEZERS,
BY REGION, 2024–2031 (USD MILLION) 317
TABLE 404 GCC COUNTRIES: CELL CULTURE MARKET FOR REFRIGERATORS & FREEZERS,
BY COUNTRY, 2024–2031 (USD MILLION) 318
TABLE 405 CELL CULTURE MARKET FOR CRYOSTORAGE SYSTEMS, BY REGION,
2024–2031 (USD MILLION) 319
TABLE 406 NORTH AMERICA: CELL CULTURE MARKET FOR CRYOSTORAGE SYSTEMS,
BY COUNTRY, 2024–2031 (USD MILLION) 319
TABLE 407 EUROPE: CELL CULTURE MARKET FOR CRYOSTORAGE SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 320
TABLE 408 ASIA PACIFIC: CELL CULTURE MARKET FOR CRYOSTORAGE SYSTEMS,
BY COUNTRY, 2024–2031 (USD MILLION) 320
TABLE 409 LATIN AMERICA: CELL CULTURE MARKET FOR CRYOSTORAGE SYSTEMS,
BY COUNTRY, 2024–2031 (USD MILLION) 321
TABLE 410 MIDDLE EAST: CELL CULTURE MARKET FOR CRYOSTORAGE SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 321
TABLE 411 GCC COUNTRIES: CELL CULTURE MARKET FOR CRYOSTORAGE SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 321
TABLE 412 CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 323
TABLE 413 CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 414 CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2024–2031 (USD MILLION) 324
TABLE 415 NORTH AMERICA: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 325
TABLE 416 EUROPE: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION,
BY COUNTRY, 2024–2031 (USD MILLION) 325
TABLE 417 ASIA PACIFIC: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 326
TABLE 418 LATIN AMERICA: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 326
TABLE 419 MIDDLE EAST: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2024–2031 (USD MILLION) 326
TABLE 420 GCC COUNTRIES: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 327
TABLE 421 CELL CULTURE MARKET FOR MONOCLONAL ANTIBODY PRODUCTION, BY REGION, 2024–2031 (USD MILLION) 328
TABLE 422 NORTH AMERICA: CELL CULTURE MARKET FOR MONOCLONAL ANTIBODY PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 328
TABLE 423 EUROPE: CELL CULTURE MARKET FOR MONOCLONAL ANTIBODY PRODUCTION,
BY COUNTRY, 2024–2031 (USD MILLION) 329
TABLE 424 ASIA PACIFIC: CELL CULTURE MARKET FOR MONOCLONAL ANTIBODY PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 329
TABLE 425 LATIN AMERICA: CELL CULTURE MARKET FOR MONOCLONAL ANTIBODY PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 330
TABLE 426 MIDDLE EAST: CELL CULTURE MARKET FOR MONOCLONAL ANTIBODY PRODUCTION, BY REGION, 2024–2031 (USD MILLION) 330
TABLE 427 GCC COUNTRIES: CELL CULTURE MARKET FOR MONOCLONAL ANTIBODY PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 330
TABLE 428 CELL CULTURE MARKET FOR VACCINE PRODUCTION, BY REGION,
2024–2031 (USD MILLION) 332
TABLE 429 NORTH AMERICA: CELL CULTURE MARKET FOR VACCINE PRODUCTION,
BY COUNTRY, 2024–2031 (USD MILLION) 332
TABLE 430 EUROPE: CELL CULTURE MARKET FOR VACCINE PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 333
TABLE 431 ASIA PACIFIC: CELL CULTURE MARKET FOR VACCINE PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 333
TABLE 432 LATIN AMERICA: CELL CULTURE MARKET FOR VACCINE PRODUCTION,
BY COUNTRY, 2024–2031 (USD MILLION) 334
TABLE 433 MIDDLE EAST: CELL CULTURE MARKET FOR VACCINE PRODUCTION, BY REGION, 2024–2031 (USD MILLION) 334
TABLE 434 GCC COUNTRIES: CELL CULTURE MARKET FOR VACCINE PRODUCTION,
BY COUNTRY, 2024–2031 (USD MILLION) 334
TABLE 435 CELL CULTURE MARKET FOR OTHER THERAPEUTIC PROTEIN PRODUCTION,
BY REGION, 2024–2031 (USD MILLION) 335
TABLE 436 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER THERAPEUTIC PROTEIN PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 336
TABLE 437 EUROPE: CELL CULTURE MARKET FOR OTHER THERAPEUTIC PROTEIN PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 336
TABLE 438 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER THERAPEUTIC PROTEIN PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 337
TABLE 439 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER THERAPEUTIC PROTEIN PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 337
TABLE 440 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER THERAPEUTIC PROTEIN PRODUCTION, BY REGION, 2024–2031 (USD MILLION) 337
TABLE 441 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER THERAPEUTIC PROTEIN PRODUCTION, BY COUNTRY, 2024–2031 (USD MILLION) 338
TABLE 442 CELL CULTURE MARKET FOR DIAGNOSTICS APPLICATION, BY REGION,
2024–2031 (USD MILLION) 339
TABLE 443 NORTH AMERICA: CELL CULTURE MARKET FOR DIAGNOSTICS APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 339
TABLE 444 EUROPE: CELL CULTURE MARKET FOR DIAGNOSTICS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 340
TABLE 445 ASIA PACIFIC: CELL CULTURE MARKET FOR DIAGNOSTICS APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 340
TABLE 446 LATIN AMERICA: CELL CULTURE MARKET FOR DIAGNOSTICS APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 341
TABLE 447 MIDDLE EAST: CELL CULTURE MARKET FOR DIAGNOSTICS APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 341
TABLE 448 GCC COUNTRIES: CELL CULTURE MARKET FOR DIAGNOSTICS APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 341
TABLE 449 CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 343
TABLE 450 CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2024–2031 (USD MILLION) 343
TABLE 451 NORTH AMERICA: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION) 344
TABLE 452 EUROPE: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION) 344
TABLE 453 ASIA PACIFIC: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION) 345
TABLE 454 LATIN AMERICA: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION) 345
TABLE 455 MIDDLE EAST: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2024–2031 (USD MILLION) 345
TABLE 456 GCC COUNTRIES: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION) 346
TABLE 457 CELL CULTURE MARKET FOR CELL & GENE THERAPY APPLICATION, BY REGION, 2024–2031 (USD MILLION) 347
TABLE 458 NORTH AMERICA: CELL CULTURE MARKET FOR CELL & GENE THERAPY APPLICATION, BY COUNTRY, 2024–2031 (USD MILLION) 348
TABLE 459 EUROPE: CELL CULTURE MARKET FOR CELL & GENE THERAPY APPLICATION,
BY COUNTRY, 2024–2031 (USD MILLION) 348
TABLE 460 ASIA PACIFIC: CELL CULTURE MARKET FOR CELL & GENE THERAPY APPLICATION, BY COUNTRY, 2024–2031 (USD MILLION) 349
TABLE 461 LATIN AMERICA: CELL CULTURE MARKET FOR CELL & GENE THERAPY APPLICATION, BY COUNTRY, 2024–2031 (USD MILLION) 349
TABLE 462 MIDDLE EAST: CELL CULTURE MARKET FOR CELL & GENE THERAPY APPLICATION, BY REGION, 2024–2031 (USD MILLION) 349
TABLE 463 GCC COUNTRIES: CELL CULTURE MARKET FOR CELL & GENE THERAPY APPLICATION, BY COUNTRY, 2024–2031 (USD MILLION) 350
TABLE 464 CELL CULTURE MARKET FOR OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 350
TABLE 465 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 351
TABLE 466 EUROPE: CELL CULTURE MARKET FOR OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 351
TABLE 467 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 352
TABLE 468 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 352
TABLE 469 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 352
TABLE 470 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER TISSUE ENGINEERING & REGENERATIVE MEDICINE APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 353
TABLE 471 CELL CULTURE MARKET FOR DRUG SCREENING & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 354
TABLE 472 NORTH AMERICA: CELL CULTURE MARKET FOR DRUG SCREENING & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 354
TABLE 473 EUROPE: CELL CULTURE MARKET FOR DRUG SCREENING & DEVELOPMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 355
TABLE 474 ASIA PACIFIC: CELL CULTURE MARKET FOR DRUG SCREENING & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 355
TABLE 475 LATIN AMERICA: CELL CULTURE MARKET FOR DRUG SCREENING & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 356
TABLE 476 MIDDLE EAST: CELL CULTURE MARKET FOR DRUG SCREENING & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 356
TABLE 477 GCC COUNTRIES: CELL CULTURE MARKET FOR DRUG SCREENING & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 356
TABLE 478 CELL CULTURE MARKET FOR OTHER APPLICATIONS, BY REGION,
2024–2031 (USD MILLION) 357
TABLE 479 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 357
TABLE 480 EUROPE: CELL CULTURE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 358
TABLE 481 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 358
TABLE 482 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 359
TABLE 483 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 359
TABLE 484 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 359
TABLE 485 CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 361
TABLE 486 CELL CULTURE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 362
TABLE 487 NORTH AMERICA: CELL CULTURE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 363
TABLE 488 EUROPE: CELL CULTURE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 363
TABLE 489 ASIA PACIFIC: CELL CULTURE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 364
TABLE 490 LATIN AMERICA: CELL CULTURE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 364
TABLE 491 MIDDLE EAST: CELL CULTURE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 364
TABLE 492 GCC COUNTRIES: CELL CULTURE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 365
TABLE 493 CELL CULTURE MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES,
BY REGION, 2024–2031 (USD MILLION) 366
TABLE 494 NORTH AMERICA: CELL CULTURE MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 366
TABLE 495 EUROPE: CELL CULTURE MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 367
TABLE 496 ASIA PACIFIC: CELL CULTURE MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 367
TABLE 497 LATIN AMERICA: CELL CULTURE MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 368
TABLE 498 MIDDLE EAST: CELL CULTURE MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 368
TABLE 499 GCC COUNTRIES: CELL CULTURE MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 368
TABLE 500 CELL CULTURE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 369
TABLE 501 NORTH AMERICA: CELL CULTURE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 370
TABLE 502 EUROPE: CELL CULTURE MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY COUNTRY, 2024–2031 (USD MILLION) 370
TABLE 503 ASIA PACIFIC: CELL CULTURE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 371
TABLE 504 LATIN AMERICA: CELL CULTURE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 371
TABLE 505 MIDDLE EAST: CELL CULTURE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 371
TABLE 506 GCC COUNTRIES: CELL CULTURE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 372
TABLE 507 CELL CULTURE MARKET FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 373
TABLE 508 NORTH AMERICA: CELL CULTURE MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 373
TABLE 509 EUROPE: CELL CULTURE MARKET FOR OTHER END USERS, BY COUNTRY,
2024–2031 (USD MILLION) 374
TABLE 510 ASIA PACIFIC: CELL CULTURE MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 374
TABLE 511 LATIN AMERICA: CELL CULTURE MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 375
TABLE 512 MIDDLE EAST: CELL CULTURE MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 375
TABLE 513 GCC COUNTRIES: CELL CULTURE MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 375
TABLE 514 CELL CULTURE MARKET, BY REGION, 2024–2031 (USD MILLION) 377
TABLE 515 NORTH AMERICA: CELL CULTURE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 378
TABLE 516 NORTH AMERICA: CELL CULTURE MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 379
TABLE 517 NORTH AMERICA: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 379
TABLE 518 NORTH AMERICA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 379
TABLE 519 NORTH AMERICA: CELL CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 380
TABLE 520 NORTH AMERICA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE, 2024–2031 (USD MILLION) 380
TABLE 521 NORTH AMERICA: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 381
TABLE 522 NORTH AMERICA: CELL CULTURE SERA MARKET, BY TYPE,
2024–2031 (USD MILLION) 381
TABLE 523 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 382
TABLE 524 NORTH AMERICA: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 382
TABLE 525 NORTH AMERICA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT,
BY TYPE, 2024–2031 (USD MILLION) 383
TABLE 526 NORTH AMERICA: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 383
TABLE 527 NORTH AMERICA: CELL CULTURE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 384
TABLE 528 NORTH AMERICA: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 384
TABLE 529 NORTH AMERICA: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 385
TABLE 530 NORTH AMERICA: CELL CULTURE MARKET, BY END USER,
2024–2031 (USD MILLION) 385
TABLE 531 INDICATIVE LIST OF CELL AND GENE THERAPIES APPROVED IN 2025-2026 386
TABLE 532 US: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 386
TABLE 533 US: CELL CULTURE CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 534 US: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 387
TABLE 535 US: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 536 US: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 388
TABLE 537 US: CELL CULTURE REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 388
TABLE 538 US: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 539 US: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 540 US: CELL CULTURE EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 541 US: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 390
TABLE 542 US: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 390
TABLE 543 US: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 391
TABLE 544 US: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 391
TABLE 545 US: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 392
TABLE 546 US: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 392
TABLE 547 CANADA: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 393
TABLE 548 CANADA: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 393
TABLE 549 CANADA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 394
TABLE 550 CANADA: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 394
TABLE 551 CANADA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 395
TABLE 552 CANADA: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 395
TABLE 553 CANADA: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 396
TABLE 554 CANADA: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 396
TABLE 555 CANADA: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 396
TABLE 556 CANADA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 397
TABLE 557 CANADA: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 397
TABLE 558 CANADA: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 398
TABLE 559 CANADA: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION,
BY TYPE, 2024–2031 (USD MILLION) 398
TABLE 560 CANADA: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 398
TABLE 561 CANADA: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 399
TABLE 562 EUROPE: CELL CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 399
TABLE 563 EUROPE: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 400
TABLE 564 EUROPE: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 400
TABLE 565 EUROPE: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 400
TABLE 566 EUROPE: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 401
TABLE 567 EUROPE: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 401
TABLE 568 EUROPE: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 402
TABLE 569 EUROPE: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 402
TABLE 570 EUROPE: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 403
TABLE 571 EUROPE: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 403
TABLE 572 EUROPE: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 404
TABLE 573 EUROPE: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 404
TABLE 574 EUROPE: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 405
TABLE 575 EUROPE: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION,
BY TYPE, 2024–2031 (USD MILLION) 405
TABLE 576 EUROPE: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY EEEE, 2024–2031 (USD MILLION) 405
TABLE 577 EUROPE: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 406
TABLE 578 GERMANY: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 406
TABLE 579 GERMANY: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 407
TABLE 580 GERMANY: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 407
TABLE 581 GERMANY: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 407
TABLE 582 GERMANY: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 408
TABLE 583 GERMANY: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 408
TABLE 584 GERMANY: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 409
TABLE 585 GERMANY: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 409
TABLE 586 GERMANY: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 409
TABLE 587 GERMANY: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 588 GERMANY: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 410
TABLE 589 GERMANY: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 411
TABLE 590 GERMANY: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION,
BY TYPE, 2024–2031 (USD MILLION) 411
TABLE 591 GERMANY: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 411
TABLE 592 GERMANY: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 412
TABLE 593 UK: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 412
TABLE 594 UK: CELL CULTURE CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 413
TABLE 595 UK: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 413
TABLE 596 UK: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 413
TABLE 597 UK: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 414
TABLE 598 UK: CELL CULTURE REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 599 UK: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 600 UK: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 601 UK: CELL CULTURE EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 602 UK: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 416
TABLE 603 UK: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 416
TABLE 604 UK: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 417
TABLE 605 UK: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 417
TABLE 606 UK: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 417
TABLE 607 UK: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 418
TABLE 608 FRANCE: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 418
TABLE 609 FRANCE: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 419
TABLE 610 FRANCE: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 419
TABLE 611 FRANCE: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 612 FRANCE: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 420
TABLE 613 FRANCE: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 420
TABLE 614 FRANCE: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 421
TABLE 615 FRANCE: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 421
TABLE 616 FRANCE: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 421
TABLE 617 FRANCE: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 422
TABLE 618 FRANCE: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 422
TABLE 619 FRANCE: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 423
TABLE 620 FRANCE: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION,
BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 621 FRANCE: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY EEEE, 2024–2031 (USD MILLION) 423
TABLE 622 FRANCE: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 424
TABLE 623 ITALY: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 424
TABLE 624 ITALY: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 425
TABLE 625 ITALY: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 425
TABLE 626 ITALY: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 425
TABLE 627 ITALY: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 426
TABLE 628 ITALY: CELL CULTURE REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 426
TABLE 629 ITALY: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 427
TABLE 630 ITALY: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 427
TABLE 631 ITALY: CELL CULTURE EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 427
TABLE 632 ITALY: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 428
TABLE 633 ITALY: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 428
TABLE 634 ITALY: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 429
TABLE 635 ITALY: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 429
TABLE 636 ITALY: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 429
TABLE 637 ITALY: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 430
TABLE 638 SPAIN: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 430
TABLE 639 SPAIN: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 431
TABLE 640 SPAIN: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 431
TABLE 641 SPAIN: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 642 SPAIN: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 432
TABLE 643 SPAIN: CELL CULTURE REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 432
TABLE 644 SPAIN: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 433
TABLE 645 SPAIN: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 433
TABLE 646 SPAIN: CELL CULTURE EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 433
TABLE 647 SPAIN: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 434
TABLE 648 SPAIN: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 434
TABLE 649 SPAIN: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 435
TABLE 650 SPAIN: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION,
BY TYPE, 2024–2031 (USD MILLION) 435
TABLE 651 SPAIN: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 435
TABLE 652 SPAIN: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 436
TABLE 653 REST OF EUROPE: CELL CULTURE MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 436
TABLE 654 REST OF EUROPE: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 437
TABLE 655 REST OF EUROPE: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE 2024–2031 (USD MILLION) 437
TABLE 656 REST OF EUROPE: CELL CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 437
TABLE 657 REST OF EUROPE: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE, 2024–2031 (USD MILLION) 438
TABLE 658 REST OF EUROPE: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 438
TABLE 659 REST OF EUROPE: CELL CULTURE SERA MARKET, BY TYPE,
2024–2031 (USD MILLION) 439
TABLE 660 REST OF EUROPE: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 439
TABLE 661 REST OF EUROPE: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 439
TABLE 662 REST OF EUROPE: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT,
BY TYPE, 2024–2031 (USD MILLION) 440
TABLE 663 REST OF EUROPE: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 440
TABLE 664 REST OF EUROPE: CELL CULTURE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 441
TABLE 665 REST OF EUROPE: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 441
TABLE 666 REST OF EUROPE: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 441
TABLE 667 REST OF EUROPE: CELL CULTURE MARKET, BY END USER,
2024–2031 (USD MILLION) 442
TABLE 668 ASIA PACIFIC: CELL CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 443
TABLE 669 ASIA PACIFIC: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 444
TABLE 670 ASIA PACIFIC: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 444
TABLE 671 ASIA PACIFIC: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 444
TABLE 672 ASIA PACIFIC: CELL CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 445
TABLE 673 ASIA PACIFIC: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 445
TABLE 674 ASIA PACIFIC: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 446
TABLE 675 ASIA PACIFIC: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 446
TABLE 676 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 447
TABLE 677 ASIA PACIFIC: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 447
TABLE 678 ASIA PACIFIC: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 448
TABLE 679 ASIA PACIFIC: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 448
TABLE 680 ASIA PACIFIC: CELL CULTURE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 449
TABLE 681 ASIA PACIFIC: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 449
TABLE 682 ASIA PACIFIC: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 450
TABLE 683 ASIA PACIFIC: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 450
TABLE 684 CHINA: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 451
TABLE 685 CHINA: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 451
TABLE 686 CHINA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 451
TABLE 687 CHINA: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 452
TABLE 688 CHINA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 452
TABLE 689 CHINA: CELL CULTURE REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 453
TABLE 690 CHINA: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 453
TABLE 691 CHINA: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 454
TABLE 692 CHINA: CELL CULTURE EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 454
TABLE 693 CHINA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 455
TABLE 694 CHINA: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 455
TABLE 695 CHINA: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 456
TABLE 696 CHINA: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION,
BY TYPE, 2024–2031 (USD MILLION) 456
TABLE 697 CHINA: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 456
TABLE 698 CHINA: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 457
TABLE 699 JAPAN: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 457
TABLE 700 JAPAN: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 458
TABLE 701 JAPAN: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 458
TABLE 702 JAPAN: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 458
TABLE 703 JAPAN: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 459
TABLE 704 JAPAN: CELL CULTURE REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 459
TABLE 705 JAPAN: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 460
TABLE 706 JAPAN: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 460
TABLE 707 JAPAN: CELL CULTURE EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 460
TABLE 708 JAPAN: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 461
TABLE 709 JAPAN: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 461
TABLE 710 JAPAN: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 462
TABLE 711 JAPAN: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION,
BY TYPE, 2024–2031 (USD MILLION) 462
TABLE 712 JAPAN: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 462
TABLE 713 JAPAN: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 463
TABLE 714 INDIA: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 463
TABLE 715 INDIA: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 464
TABLE 716 INDIA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 464
TABLE 717 INDIA: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 464
TABLE 718 INDIA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 465
TABLE 719 INDIA: CELL CULTURE REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 465
TABLE 720 INDIA: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 721 INDIA: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 722 INDIA: CELL CULTURE EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 723 INDIA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 467
TABLE 724 INDIA: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 467
TABLE 725 INDIA: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 468
TABLE 726 INDIA: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 468
TABLE 727 INDIA: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 468
TABLE 728 INDIA: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 469
TABLE 729 SOUTH KOREA: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 469
TABLE 730 SOUTH KOREA: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 470
TABLE 731 SOUTH KOREA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 470
TABLE 732 SOUTH KOREA: CELL CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 470
TABLE 733 SOUTH KOREA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE, 2024–2031 (USD MILLION) 471
TABLE 734 SOUTH KOREA: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 471
TABLE 735 SOUTH KOREA: CELL CULTURE SERA MARKET, BY TYPE,
2024–2031 (USD MILLION) 472
TABLE 736 SOUTH KOREA: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 472
TABLE 737 SOUTH KOREA: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 472
TABLE 738 SOUTH KOREA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 473
TABLE 739 SOUTH KOREA: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 473
TABLE 740 SOUTH KOREA: CELL CULTURE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 474
TABLE 741 SOUTH KOREA: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 474
TABLE 742 SOUTH KOREA: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 474
TABLE 743 SOUTH KOREA: CELL CULTURE MARKET, BY END USER,
2024–2031 (USD MILLION) 475
TABLE 744 AUSTRALIA: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 475
TABLE 745 AUSTRALIA: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 476
TABLE 746 AUSTRALIA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 476
TABLE 747 AUSTRALIA: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 476
TABLE 748 AUSTRALIA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 477
TABLE 749 AUSTRALIA: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 477
TABLE 750 AUSTRALIA: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 478
TABLE 751 AUSTRALIA: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 478
TABLE 752 AUSTRALIA: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 478
TABLE 753 AUSTRALIA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 479
TABLE 754 AUSTRALIA: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 479
TABLE 755 AUSTRALIA: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 480
TABLE 756 AUSTRALIA: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION,
BY TYPE, 2024–2031 (USD MILLION) 480
TABLE 757 AUSTRALIA: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 480
TABLE 758 AUSTRALIA: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 481
TABLE 759 REST OF ASIA PACIFIC: CELL CULTURE MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 481
TABLE 760 REST OF ASIA PACIFIC: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 482
TABLE 761 REST OF ASIA PACIFIC: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 482
TABLE 762 REST OF ASIA PACIFIC: CELL CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 483
TABLE 763 REST OF ASIA PACIFIC: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE, 2024–2031 (USD MILLION) 483
TABLE 764 REST OF ASIA PACIFIC: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 484
TABLE 765 REST OF ASIA PACIFIC: CELL CULTURE SERA MARKET, BY TYPE,
2024–2031 (USD MILLION) 484
TABLE 766 REST OF ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 485
TABLE 767 REST OF ASIA PACIFIC: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 485
TABLE 768 REST OF ASIA PACIFIC: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT,
BY TYPE, 2024–2031 (USD MILLION) 486
TABLE 769 REST OF ASIA PACIFIC: CELL CULTURE MARKET FOR STORAGE EQUIPMENT,
BY TYPE, 2024–2031 (USD MILLION) 486
TABLE 770 REST OF ASIA PACIFIC: CELL CULTURE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 487
TABLE 771 REST OF ASIA PACIFIC: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 487
TABLE 772 REST OF ASIA PACIFIC: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 487
TABLE 773 REST OF ASIA PACIFIC: CELL CULTURE MARKET, BY END USER,
2024–2031 (USD MILLION) 488
TABLE 774 LATIN AMERICA: CELL CULTURE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 488
TABLE 775 LATIN AMERICA: CELL CULTURE MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 489
TABLE 776 LATIN AMERICA: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 489
TABLE 777 LATIN AMERICA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 489
TABLE 778 LATIN AMERICA: CELL CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 490
TABLE 779 LATIN AMERICA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE, 2024–2031 (USD MILLION) 490
TABLE 780 LATIN AMERICA: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 491
TABLE 781 LATIN AMERICA: CELL CULTURE SERA MARKET, BY TYPE,
2024–2031 (USD MILLION) 491
TABLE 782 LATIN AMERICA: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 492
TABLE 783 LATIN AMERICA: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 492
TABLE 784 LATIN AMERICA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 493
TABLE 785 LATIN AMERICA: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 493
TABLE 786 LATIN AMERICA: CELL CULTURE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 494
TABLE 787 LATIN AMERICA: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 494
TABLE 788 LATIN AMERICA: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 494
TABLE 789 LATIN AMERICA: CELL CULTURE MARKET, BY END USER,
2024–2031 (USD MILLION) 495
TABLE 790 BRAZIL: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 495
TABLE 791 BRAZIL: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 496
TABLE 792 BRAZIL: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 496
TABLE 793 BRAZIL: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 496
TABLE 794 BRAZIL: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 497
TABLE 795 BRAZIL: CELL CULTURE REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 497
TABLE 796 BRAZIL: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 498
TABLE 797 BRAZIL: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 498
TABLE 798 BRAZIL: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 498
TABLE 799 BRAZIL: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 499
TABLE 800 BRAZIL: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 499
TABLE 801 BRAZIL: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 500
TABLE 802 BRAZIL: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION,
BY TYPE, 2024–2031 (USD MILLION) 500
TABLE 803 BRAZIL: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 500
TABLE 804 BRAZIL: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 501
TABLE 805 MEXICO: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 501
TABLE 806 MEXICO: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 502
TABLE 807 MEXICO: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 502
TABLE 808 MEXICO: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 502
TABLE 809 MEXICO: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 503
TABLE 810 MEXICO: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 503
TABLE 811 MEXICO: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 504
TABLE 812 MEXICO: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 504
TABLE 813 MEXICO: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 504
TABLE 814 MEXICO: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 505
TABLE 815 MEXICO: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 505
TABLE 816 MEXICO: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 506
TABLE 817 MEXICO: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION,
BY TYPE, 2024–2031 (USD MILLION) 506
TABLE 818 MEXICO: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 506
TABLE 819 MEXICO: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 507
TABLE 820 REST OF LATIN AMERICA: CELL CULTURE MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 507
TABLE 821 REST OF LATIN AMERICA: CELL CULTURE CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 508
TABLE 822 REST OF LATIN AMERICA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 508
TABLE 823 REST OF LATIN AMERICA: CELL CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 509
TABLE 824 REST OF LATIN AMERICA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA,
BY TYPE, 2024–2031 (USD MILLION) 509
TABLE 825 REST OF LATIN AMERICA: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 510
TABLE 826 REST OF LATIN AMERICA: CELL CULTURE SERA MARKET, BY TYPE,
2024–2031 (USD MILLION) 510
TABLE 827 REST OF LATIN AMERICA: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 511
TABLE 828 REST OF LATIN AMERICA: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 511
TABLE 829 REST OF LATIN AMERICA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 512
TABLE 830 REST OF LATIN AMERICA: CELL CULTURE MARKET FOR STORAGE EQUIPMENT,
BY TYPE, 2024–2031 (USD MILLION) 512
TABLE 831 REST OF LATIN AMERICA: CELL CULTURE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 513
TABLE 832 REST OF LATIN AMERICA: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 513
TABLE 833 REST OF LATIN AMERICA: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 514
TABLE 834 REST OF LATIN AMERICA: CELL CULTURE MARKET, BY END USER,
2024–2031 (USD MILLION) 514
TABLE 835 MIDDLE EAST: CELL CULTURE MARKET, BY REGION, 2024–2031 (USD MILLION) 515
TABLE 836 MIDDLE EAST: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 515
TABLE 837 MIDDLE EAST: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 515
TABLE 838 MIDDLE EAST: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 516
TABLE 839 MIDDLE EAST: CELL CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 516
TABLE 840 MIDDLE EAST: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 517
TABLE 841 MIDDLE EAST: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 517
TABLE 842 MIDDLE EAST: CELL CULTURE SERA MARKET, BY TYPE,
2024–2031 (USD MILLION) 518
TABLE 843 MIDDLE EAST: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 518
TABLE 844 MIDDLE EAST: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 518
TABLE 845 MIDDLE EAST: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 519
TABLE 846 MIDDLE EAST: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 519
TABLE 847 MIDDLE EAST: CELL CULTURE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 520
TABLE 848 MIDDLE EAST: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 520
TABLE 849 MIDDLE EAST: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 520
TABLE 850 MIDDLE EAST: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 521
TABLE 851 GCC COUNTRIES: CELL CULTURE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 521
TABLE 852 GCC COUNTRIES: CELL CULTURE MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 522
TABLE 853 GCC COUNTRIES: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 522
TABLE 854 GCC COUNTRIES: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 522
TABLE 855 GCC COUNTRIES: CELL CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 523
TABLE 856 GCC COUNTRIES: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE, 2024–2031 (USD MILLION) 523
TABLE 857 GCC COUNTRIES: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 524
TABLE 858 GCC COUNTRIES: CELL CULTURE SERA MARKET, BY TYPE,
2024–2031 (USD MILLION) 524
TABLE 859 GCC COUNTRIES: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 525
TABLE 860 GCC COUNTRIES: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 525
TABLE 861 GCC COUNTRIES: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 525
TABLE 862 GCC COUNTRIES: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 526
TABLE 863 GCC COUNTRIES: CELL CULTURE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 526
TABLE 864 GCC COUNTRIES: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 526
TABLE 865 GCC COUNTRIES: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 527
TABLE 866 GCC COUNTRIES: CELL CULTURE MARKET, BY END USER,
2024–2031 (USD MILLION) 527
TABLE 867 SAUDI ARABIA: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 528
TABLE 868 SAUDI ARABIA: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 528
TABLE 869 SAUDI ARABIA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 528
TABLE 870 SAUDI ARABIA: CELL CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 529
TABLE 871 SAUDI ARABIA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE, 2024–2031 (USD MILLION) 529
TABLE 872 SAUDI ARABIA: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 530
TABLE 873 SAUDI ARABIA: CELL CULTURE SERA MARKET, BY TYPE,
2024–2031 (USD MILLION) 530
TABLE 874 SAUDI ARABIA: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 530
TABLE 875 SAUDI ARABIA: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 531
TABLE 876 SAUDI ARABIA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 531
TABLE 877 SAUDI ARABIA: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 531
TABLE 878 SAUDI ARABIA: CELL CULTURE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 532
TABLE 879 SAUDI ARABIA: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 532
TABLE 880 SAUDI ARABIA: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 532
TABLE 881 SAUDI ARABIA: CELL CULTURE MARKET, BY END USER,
2024–2031 (USD MILLION) 533
TABLE 882 UAE: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 533
TABLE 883 UAE: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 534
TABLE 884 UAE: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 534
TABLE 885 UAE: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 534
TABLE 886 UAE: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 535
TABLE 887 UAE: CELL CULTURE REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 535
TABLE 888 UAE: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 536
TABLE 889 UAE: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 536
TABLE 890 UAE: CELL CULTURE EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 536
TABLE 891 UAE: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 537
TABLE 892 UAE: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 537
TABLE 893 UAE: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 538
TABLE 894 UAE: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 538
TABLE 895 UAE: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 538
TABLE 896 UAE: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 539
TABLE 897 REST OF GCC COUNTRIES: CELL CULTURE MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 539
TABLE 898 REST OF GCC COUNTRIES: CELL CULTURE CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 540
TABLE 899 REST OF GCC COUNTRIES: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 540
TABLE 900 REST OF GCC COUNTRIES: CELL CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 540
TABLE 901 REST OF GCC COUNTRIES: CELL CULTURE MARKET FOR SERUM-FREE MEDIA,
BY TYPE, 2024–2031 (USD MILLION) 541
TABLE 902 REST OF GCC COUNTRIES: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 541
TABLE 903 REST OF GCC COUNTRIES: CELL CULTURE SERA MARKET, BY TYPE,
2024–2031 (USD MILLION) 542
TABLE 904 REST OF GCC COUNTRIES: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 542
TABLE 905 REST OF GCC COUNTRIES: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 542
TABLE 906 REST OF GCC COUNTRIES: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 543
TABLE 907 REST OF GCC COUNTRIES: CELL CULTURE MARKET FOR STORAGE EQUIPMENT,
BY TYPE, 2024–2031 (USD MILLION) 543
TABLE 908 REST OF GCC COUNTRIES: CELL CULTURE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 544
TABLE 909 REST OF GCC COUNTRIES: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 544
TABLE 910 REST OF GCC COUNTRIES: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 544
TABLE 911 REST OF GCC COUNTRIES: CELL CULTURE MARKET, BY END USER,
2024–2031 (USD MILLION) 545
TABLE 912 REST OF MIDDLE EAST: CELL CULTURE MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 545
TABLE 913 REST OF MIDDLE EAST: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 546
TABLE 914 REST OF MIDDLE EAST: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 546
TABLE 915 REST OF MIDDLE EAST: CELL CULTURE MEDIA MARKET, BY TYPE,
2024–2031 (USD MILLION) 546
TABLE 916 REST OF MIDDLE EAST: CELL CULTURE MARKET FOR SERUM-FREE MEDIA,
BY TYPE, 2024–2031 (USD MILLION) 547
TABLE 917 REST OF MIDDLE EAST: CELL CULTURE REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 547
TABLE 918 REST OF MIDDLE EAST: CELL CULTURE SERA MARKET, BY TYPE,
2024–2031 (USD MILLION) 548
TABLE 919 REST OF MIDDLE EAST: CELL CULTURE VESSELS MARKET, BY TYPE,
2024–2031 (USD MILLION) 548
TABLE 920 REST OF MIDDLE EAST: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 548
TABLE 921 REST OF MIDDLE EAST: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE, 2024–2031 (USD MILLION) 549
TABLE 922 REST OF MIDDLE EAST: CELL CULTURE MARKET FOR STORAGE EQUIPMENT,
BY TYPE, 2024–2031 (USD MILLION) 549
TABLE 923 REST OF MIDDLE EAST: CELL CULTURE MARKET, BY APPLICATION
2024–2031 (USD MILLION) 550
TABLE 924 REST OF MIDDLE EAST: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY TYPE, 2024–2031 (USD MILLION) 550
TABLE 925 REST OF MIDDLE EAST: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 550
TABLE 926 REST OF MIDDLE EAST: CELL CULTURE MARKET, BY END USER,
2024–2031 (USD MILLION) 551
TABLE 927 AFRICA: CELL CULTURE MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 551
TABLE 928 AFRICA: CELL CULTURE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 552
TABLE 929 AFRICA: CELL CULTURE SERA, MEDIA, AND REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 552
TABLE 930 AFRICA: CELL CULTURE MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 552
TABLE 931 AFRICA: CELL CULTURE MARKET FOR SERUM-FREE MEDIA, BY TYPE,
2024–2031 (USD MILLION) 553
TABLE 932 AFRICA: CELL CULTURE REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 553
TABLE 933 AFRICA: CELL CULTURE SERA MARKET, BY TYPE, 2024–2031 (USD MILLION) 554
TABLE 934 AFRICA: CELL CULTURE VESSELS MARKET, BY TYPE, 2024–2031 (USD MILLION) 554
TABLE 935 AFRICA: CELL CULTURE EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 554
TABLE 936 AFRICA: CELL CULTURE MARKET FOR SUPPORTING EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 555
TABLE 937 AFRICA: CELL CULTURE MARKET FOR STORAGE EQUIPMENT, BY TYPE,
2024–2031 (USD MILLION) 555
TABLE 938 AFRICA: CELL CULTURE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 556
TABLE 939 AFRICA: CELL CULTURE MARKET FOR BIOPHARMACEUTICAL PRODUCTION,
BY TYPE, 2024–2031 (USD MILLION) 556
TABLE 940 AFRICA: CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY TYPE, 2024–2031 (USD MILLION) 556
TABLE 941 AFRICA: CELL CULTURE MARKET, BY END USER, 2024–2031 (USD MILLION) 557
TABLE 942 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL CULTURE MARKET, JANUARY 2023–MAY 2026 558
TABLE 943 CELL CULTURE MARKET: DEGREE OF COMPETITION 562
TABLE 944 CELL CULTURE MARKET: REGIONAL FOOTPRINT, 2025 566
TABLE 945 CELL CULTURE MARKET: PRODUCT FOOTPRINT, 2025 567
TABLE 946 CELL CULTURE MARKET: APPLICATION FOOTPRINT, 2025 568
TABLE 947 CELL CULTURE MARKET: END-USER FOOTPRINT, 2025 569
TABLE 948 CELL CULTURE MARKET: DETAILED LIST OF KEY STARTUPS/SMES, 2025 571
TABLE 949 CELL CULTURE MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT AND REGION ,2025 572
TABLE 950 CELL CULTURE MARKET: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 575
TABLE 951 CELL CULTURE MARKET: DEALS, JANUARY 2023–MAY 2026 575
TABLE 952 CELL CULTURE MARKET: EXPANSIONS, JANUARY 2023–MAY 2026 576
TABLE 953 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 578
TABLE 954 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 579
TABLE 955 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES 592
TABLE 956 THERMO FISHER SCIENTIFIC INC.: DEALS 594
TABLE 957 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS 595
TABLE 958 DANAHER CORPORATION: COMPANY OVERVIEW 597
TABLE 959 DANAHER CORPORATION: PRODUCTS OFFERED 598
TABLE 960 DANAHER CORPORATION: PRODUCT LAUNCHES 608
TABLE 961 DANAHER CORPORATION: DEALS 609
TABLE 962 DANAHER CORPORATION: EXPANSIONS 610
TABLE 963 DANAHER CORPORATION: OTHER DEVELOPMENTS 611
TABLE 964 MERCK KGAA: COMPANY OVERVIEW 613
TABLE 965 MERCK KGAA: PRODUCTS OFFERED 614
TABLE 966 MERCK KGAA: PRODUCT LAUNCHES 621
TABLE 967 MERCK KGAA: DEALS 621
TABLE 968 MERCK KGAA: EXPANSIONS 622
TABLE 969 SARTORIUS AG: COMPANY OVERVIEW 625
TABLE 970 SARTORIUS AG: PRODUCTS OFFERED 626
TABLE 971 SARTORIUS AG: PRODUCT LAUNCHES 634
TABLE 972 SARTORIUS AG.: DEALS 635
TABLE 973 SARTORIUS AG: EXPANSIONS, JANUARY 2023–MAY 2026 637
TABLE 974 CORNING INCORPORATED: COMPANY OVERVIEW 640
TABLE 975 CORNING INCORPORATED: PRODUCTS OFFERED 641
TABLE 976 CORNING INCORPORATED: DEALS 650
TABLE 977 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW 652
TABLE 978 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED 653
TABLE 979 FUJIFILM HOLDINGS CORPORATION: PRODUCT LAUNCHES 659
TABLE 980 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2023–MAY 2026 660
TABLE 981 FUJIFILM HOLDINGS CORPORATION: OTHER DEVELOPMENTS 660
TABLE 982 BD: COMPANY OVERVIEW 661
TABLE 983 BD: PRODUCTS OFFERED 662
TABLE 984 BD: PRODUCT LAUNCHES 664
TABLE 985 BD: DEALS, JANUARY 2023–MAY 2026 664
TABLE 986 BD: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 665
TABLE 987 EPPENDORF SE: COMPANY OVERVIEW 666
TABLE 988 EPPENDORF SE: PRODUCTS OFFERED 667
TABLE 989 EPPENDORF SE: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 672
TABLE 990 EPPENDORF SE: EXPANSIONS 673
TABLE 991 LONZA: COMPANY OVERVIEW 674
TABLE 992 LONZA: PRODUCTS OFFERED 675
TABLE 993 LONZA: PRODUCT LAUNCHES 678
TABLE 994 LONZA: DEALS, JANUARY 2023–MAY 2026 678
TABLE 995 GETINGE: COMPANY OVERVIEW 679
TABLE 996 GETINGE: PRODUCTS OFFERED 680
TABLE 997 GETINGE: PRODUCT LAUNCHES 681
TABLE 998 GETINGE: DEALS, JANUARY 2023–MAY 2026 682
TABLE 999 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 683
TABLE 1000 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 684
TABLE 1001 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES 686
TABLE 1002 AGILENT TECHNOLOGIES, INC.: DEALS 687
TABLE 1003 AGILENT TECHNOLOGIES, INC.: EXPANSIONS 687
TABLE 1004 HIMEDIA LABORATORIES: COMPANY OVERVIEW 688
TABLE 1005 HIMEDIA LABORATORIES: PRODUCTS OFFERED 688
TABLE 1006 BIO-TECHNE: COMPANY OVERVIEW 692
TABLE 1007 BIO-TECHNE: PRODUCTS OFFERED 693
TABLE 1008 BIO-TECHNE: PRODUCT LAUNCHES 697
TABLE 1009 BIO-TECHNE: DEALS 697
TABLE 1010 BIO-TECHNE: EXPANSIONS 698
TABLE 1011 MILTENYI BIOTEC: COMPANY OVERVIEW 699
TABLE 1012 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW 701
TABLE 1013 SOLIDA BIOTECH GMBH: COMPANY OVERVIEW 704
TABLE 1014 CAISSON LABS: COMPANY OVERVIEW 705
TABLE 1015 PROMOCELL GMBH: COMPANY OVERVIEW 706
TABLE 1016 INVIVOGEN: COMPANY OVERVIEW 707
TABLE 1017 PAN-BIOTECH: COMPANY OVERVIEW 708
TABLE 1018 CELLEXUS: COMPANY OVERVIEW 709
TABLE 1019 MEISSNER FILTRATION PRODUCTS, INC.: COMPANY OVERVIEW 710
TABLE 1020 ADOLF KÜHNER AG: COMPANY OVERVIEW 712
TABLE 1021 ADVANCION CORPORATION: COMPANY OVERVIEW 713
TABLE 1022 BIOSPHERIX LLC: COMPANY OVERVIEW 714
TABLE 1023 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 723
TABLE 1024 RISK ASSESSMENT 726

LIST OF FIGURES

FIGURE 1 CELL CULTURE MARKET SEGMENTATION 62
FIGURE 2 CELL CULTURE MARKET REGIONS COVERED 63
FIGURE 3 CELL CULTURE MARKET: YEARS CONSIDERED 63
FIGURE 4 MARKET SCENARIO 67
FIGURE 5 GLOBAL CELL CULTURE MARKET, 2024–2031 67
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CELL CULTURE MARKET, 2023–2026 68
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF CELL CULTURE MARKET 69
FIGURE 8 HIGH-GROWTH SEGMENTS IN CELL CULTURE MARKET, 2026–2031 70
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CELL CULTURE MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 71
FIGURE 10 INCREASING ADOPTION OF SINGLE-USE TECHNOLOGIES TO DRIVE MARKET GROWTH 72
FIGURE 11 US AND SERA, MEDIA, REAGENTS ACCOUNTED FOR LARGEST SHARE OF CELL CULTURE MARKET IN NORTH AMERICA IN 2025 73
FIGURE 12 ASIA PACIFIC LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL CELL CULTURE MARKET DURING FORECAST PERIOD 74
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 74
FIGURE 14 CELL CULTURE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 75
FIGURE 15 NUMBER OF ANTIBODY THERAPEUTICS GRANTED FIRST APPROVAL IN US/EU, 2012−2025 81
FIGURE 16 NUMBER OF BIOSIMILARS APPROVED AND LAUNCHED, 2015−2025 81
FIGURE 17 CLINICAL TRIAL OVERVIEW OF TISSUE-ENGINEERED PRODUCTS, 2019–2025 83
FIGURE 18 CELL CULTURE MARKET: PORTER’S FIVE FORCES ANALYSIS 92
FIGURE 19 GLOBAL GDP GROWTH, 2020–2030 94
FIGURE 20 CELL CULTURE MARKET: VALUE CHAIN ANALYSIS 95
FIGURE 21 CELL CULTURE MARKET ECOSYSTEM 97
FIGURE 22 AVERAGE SELLING PRICE TREND OF CELL CULTURE PRODUCTS,
2023–2025 (USD) 101
FIGURE 23 AVERAGE SELLING PRICE OF CELL CULTURE PRODUCTS, BY REGION, 2025 (USD) 102
FIGURE 24 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN CELL CULTURE MARKET 107
FIGURE 25 CELL CULTURE MARKET: STARTUP FUNDING FOR GENE, CELL, AND RNA THERAPY COMPANIES, 2025–2026 (USD MILLION) 107
FIGURE 26 CELL CULTURE MARKET: INVESTMENTS BY DEAL TYPE FOR ALL REGIONS,
Q4 2025 109
FIGURE 27 TOP APPLICANTS/OWNERS (COMPANIES) FOR CELL CULTURE PATENTS,
2015–2025 119
FIGURE 28 IMPACT OF AI/GEN AI ON CELL CULTURE MARKET 123
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CELL CULTURE PRODUCTS 134
FIGURE 30 KEY BUYING CRITERIA, BY END USER 135
FIGURE 31 ONGOING CLINICAL TRIALS BY PHASE AND THERAPEUTIC APPROACH 347
FIGURE 32 NORTH AMERICA: CELL CULTURE MARKET SNAPSHOT 378
FIGURE 33 ASIA PACIFIC: CELL CULTURE MARKET SNAPSHOT 443
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN CELL CULTURE MARKET,
2021–2025 (USD BILLION) 561
FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CELL CULTURE MARKET, 2025 562
FIGURE 36 CELL CULTURE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 565
FIGURE 37 CELL CULTURE MARKET: COMPANY FOOTPRINT, 2025 566
FIGURE 38 CELL CULTURE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 571
FIGURE 39 EV/EBITDA OF KEY VENDORS, 2026 573
FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS, 2026 573
FIGURE 41 CELL CULTURE MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 574
FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 579
FIGURE 43 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 598
FIGURE 44 MERCK KGAA: COMPANY SNAPSHOT (2025) 614
FIGURE 45 SARTORIUS AG: COMPANY SNAPSHOT (2025) 626
FIGURE 46 CORNING INCORPORATED: COMPANY SNAPSHOT (2025) 641
FIGURE 47 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2025) 653
FIGURE 48 BD: COMPANY SNAPSHOT (2025) 662
FIGURE 49 EPPENDORF SE: COMPANY SNAPSHOT (2024) 667
FIGURE 50 LONZA: COMPANY SNAPSHOT (2025) 675
FIGURE 51 GETINGE: COMPANY SNAPSHOT (2025) 680
FIGURE 52 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 684
FIGURE 53 BIO-TECHNE: COMPANY SNAPSHOT (2025) 693
FIGURE 54 CELL CULTURE MARKET: RESEARCH DESIGN 715
FIGURE 55 CELL CULTURE MARKET: BREAKDOWN OF PRIMARIES 717
FIGURE 56 GLOBAL CELL CULTURE MARKET ESTIMATION, 2025 718
FIGURE 57 CELL CULTURE MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025) 719
FIGURE 58 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC:
REVENUE ANALYSIS (2025) 719
FIGURE 59 CELL CULTURE MARKET: INSIGHTS FROM PRIMARIES 720
FIGURE 60 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 721
FIGURE 61 CELL CULTURE MARKET: CAGR PROJECTIONS 722
FIGURE 62 CELL CULTURE MARKET: DATA TRIANGULATION 724

---

---